

Vidarbha Youth Welfare Society's
INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH
Borgaon (Meghe), Wardha (M.S.)


Representative documents for Books, Chapters published and conference proceedings

Vidarbha Youth Welfare Society's
INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH
Borgaon (Meghe), Wardha (M.S.)

Table of content

Sr. No.	Academic Session	Title of Book/Chapter	Page No.
1	2017-18	Nil	--
2	2018-19	Improvement in cilnidipine solubility by amorphous solid dispersion and formulation of interpenetrating polymer network microspheres for sustained release	01-21
		Dual release floating pulsatile drug delivery system of atenolol for the treatment of hypertension	
		Design, synthesis, characterization and in-vivo evaluation of anti-inflammatory activity of substituted thiazolotriazoles	
		Quality Evaluation of Water in Wardha Zilla	
		Characterization of Polymorphic Behaviour of Daclatasvir Dihydrochloride using Instrumental Techniques	
		Formulation and Optimization of Deflazacort Oral Films using Boxhehnken Design	
		Design, development and evaluation of pH responsive microspheres containing Celecoxib for Colon targeting by using Boxbehnken Design	
		Design, Development and Comparative Evaluation of Medicated Anti-dandruff Shampoo with Marketed Formulations	
		Formulation and Characterization of Nateglinide Cystallo-Co-Agglomerates	
		Formulation and Evaluation of Enteric-Coated Extended Release Tablet	
		Improvement In Solubility and Dissolution Behaviour of a Poorly Water Soluble Drug Cilnidipine Using Soluplus By Solid Dispersion Technique	
		Formulation Development of Topical Gel Loaded with Nanosponges Of Anti-Fungal Drug	
		Analgesic And Anti-Inflammatory Potency Of Flavonoids Extract From Ricinus Communis	
		Pharmacological Effects of Nettle Root Extract (Urtica-Dioica) On Benign Prostatic Hyperplasia	
		A Comprehensive Study on Pharmacological Effects of Gallic Acid Against Alzheimer'S Disease In Albino Rats	
		Pharmacological Screening of Polyherbal Formulation on Polycystic Ovarian Syndrome in Female Albino Rats	
		A Linear Qsar Model For Predicting The Enzyme By Arylbenzoxazole Derivatives Characterization By Docking Studies	




 (Dr. R. O. Ganjivale)
 Principal
 PRINCIPAL
 Institute of Pharmaceutical Education & Research
 Borgaon (Meghe), Wardha

		Effects Of Different Homeopathic Potencies of Gymnema Sylvestre In Treatment Of Alloxan Induced Diabetes	
		Preparation of floating mucoadhesive tablet of a drug having narrow absorption in the gastrointestinal tract	
		A Concise Handbook of Pharmacology-I	
3	2019-20	A Concise Handbook of Pharmacology-II.	22-41
		Focus on pharmacology and toxicology.	
		Nanopharmaceuticals for the Improved Treatment of Cerebral Stroke. In: Rai M, Yadav Y, Editors. "Nanobiotechnology in Neurodegenerative Diseases.	
		Nanomedicines for improved antiretroviral therapy in Neuro-AIDS. In: Rai M, Yadav Y, Editors. "Nanobiotechnology in Neurodegenerative Diseases.	
		Development and in-vivo evaluation of intranasal dolutegravir sodium nanoparticles for brain targeting in neuroAIDS	
		Intranasal gelling mucoadhesive microspheres of carboxymethyl fenugreek gum and chitosan for improving bioavailability of gentamicin	
		TPS Pathophysiology.	
4	2020-21	Medicinal Chemistry III.	42-64
		Application of Nanotechnology in Transdermal Drug Delivery. In: Mahendra Rai, Mehdi Razzaghi Abyaneh, Avinash P Ingle.Editors. Nanobiotechnology in Diagnosis, Drug Delivery and Treatment.	
		Social and Preventive Pharmacy.	
		Recent facts & Global prospectives of nutraceuticals in medicine. In: Dangre P, Mahapatra D, Editors. Nutraceutical Delivery System.	
		Liposomal Delivery System for the Effective Delivery of Nutraceuticals and Functional Foods. In: Dangre P, Mahapatra D, Editors. Nutraceutical Delivery System.	
		Concise Course in Pharmacology-I	
5	2021-22	A Text-Book of Quality Control and Quality Assurance	65-90
		Pharmaceutical Biotechnology	
		A Text-Book of Human Anatomy and Physiology	
		A Text-Book of Pharmaceutical Chemistry-I	
		Progress in nanotechnology-based targeted cancer treatment ,In: Mahajan NM, Siani A, Raut NA, Dhoble SJ. Photophysics and Nanophysics in Therapeutics	
		Nanovaccines against viral infections: Current trends and future prospects. In Mahendra Rai and Alka Yadav (Eds) NANOTECHNOLOGICAL APPLICATIONS IN VIROLOGY	
		Boron: A micronutrient yet indispensable. In Prabhat Chaturvedi (Ed). Advanced Research and Review in Agronomy	



(Signature)
 (Dr. R. O. Ganjivale)
 Principal
 PRINCIPAL
 Institute of Pharmaceutical Education & Research
 Borgun (Meghe), Wardha

IMPROVEMENT IN CILNIDIPINE SOLUBILITY BY AMORPHOUS SOLID DISPERSION AND FORMULATION OF INTERPENETRATING POLYMER NETWORK MICROSPHERES FOR SUSTAINED RELEASE

Amit Kuhikar and Shagufta Khan*

Department of Pharmaceutics, Institute of Pharmaceutical Education and Research, Borgaon (Meghe) Wardha, Maharashtra, India

ABSTRACT

Cilnidipine a calcium channel blocker has poor water solubility, short half-life and show poor bioavailability. Therefore, in the present investigation amorphous solid dispersion of cilnidipine was prepared and then loaded into interpenetrating polymer network (IPN) microspheres to achieve sustained release. Phase solubility of cilnidipine with solutol gave AL type curve therefore, solid dispersion was prepared by melting method, taking cilnidipine: solutol 1:1. Solubility was increased 86 folds in water (saturated solubility of cilnidipine, 0.0022 mg/ml) with solid dispersion due to amorphization of drug which was revealed in the XRD and DSC analysis of solid dispersion. Amorphous solid dispersion was used to prepare IPN microspheres. IPN microspheres were prepared using chitosan and PVA by emulsion internal phase crosslinking. Formulation and optimization was done using Box-Behnken Design. The three independent variables were amount of chitosan, PVA and ratio of chitosan:TPP, while the dependent variables were entrapment efficiency and drug release in 12 h. The level of chitosan and PVA was between 50 to 100 mg per 10 ml internal phase and ratio of chitosan: TPP was varied from 2.5 to 3. Percent entrapment efficiency was found to increase with the increase in the amount of chitosan while it was found to decrease with the decrease in chitosan: TPP ratio. Drug release was found to decrease with the increase in the amount of chitosan and decrease in the amount of PVA. IPN microspheres prepared with chitosan, 50 mg; PVA, 75 mg; and chitosan: TPP 2.5 in the 10 ml of the internal phase gave maximum entrapment efficiency ($83.87 \pm 1.5\%$) and $83.29 \pm 0.9\%$ drug release in 12 h, therefore considered optimum.



(Signature)
 (Dr. R. O. Ganjivale)
 Principal
 PRINCIPAL
 Institute of Pharmaceutical Education & Research
 Borgaon (Meghe), Wardha

OP-01

**DUAL RELEASE FLOATING PULSATILE DRUG DELIVERY SYSTEM OF ATENOLOL
FOR THE TREATMENT OF HYPERTENSION**

Sonam S. Kunjekar, Dilesh J. Singhavi*

Institute of Pharmaceutical Education and Research, Borgaon (Meghe) Wardha,
Maharashtra, India

ABSTRACT

Hypertension shows circadian rhythm which requires release of drugs at the time of symptoms. Blood pressure appears too elevated during night at 7 pm and early in the morning at 4 am. Atenolol is an anti-hypertensive drug, which has narrow absorption window. Therefore, the present study was aimed at preparing and evaluating floating pulsatile capsules for dual release of atenolol in the stomach for effective treatment of hypertension. The floating pulsatile capsule consists of different parts: formaldehyde treated capsule body; untreated cap; a plug layer, containing polymer; atenolol-containing core tablets and swellable polymer layer. The plug layer composed of hydroxypropyl methylcellulose of two different grades (K4M and E50) and xanthan gum alone or in combination. Developed formulations were evaluated for weight variation, drug content, floating behaviour and in-vitro release behaviour. The results showed that lag time of the formulations can be adjusted by composition of plug layer. Thus, formulated floating pulsatile capsule may release first pulse of drug immediately after administration to cover first point of symptom. The results may be expected to release after a lag time to cover the early morning for the treatment of hypertension.



(Signature)
(Dr. R. O. Ganjivale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgaon (Meghe), Wardha

OP-03

DESIGN, SYNTHESIS, CHARACTERIZATION AND IN-VIVO EVALUATION OF ANTI-INFLAMMATORY ACTIVITY OF SUBSTITUTED THIAZOLOTRIAZOLES

N. A. Karande* L. G. Rathi

Department of Pharmaceutical Chemistry, Institute of Pharmaceutical Education and Research, Borgaon (Meghe), Wardha 442001, India

ABSTRACT

In the present work, a simple and efficient practical method for synthesis of a new series of 2-{{5-(2-chlorophenyl)-4H-1,2,4-triazol-3-yl}sulfanyl}-1-(substituted phenyl) ethanone (7a-l) and 2-(2-chlorophenyl)-6-(4-substituted phenyl)-1,3-thiazolo [3,2-b]-1,2,4-triazole (8a-l) was achieved. The structures of these new heterocyclic compounds bearing both thiazole and triazole ring arrangements were supported by spectral (IR, ¹H and ¹³C NMR, Mass) and elemental (C, H, N, S) analysis. These compounds were screened for anti-inflammatory activity by Carrageenan induced rat paw edema method. The results proved that many of the synthesized derivatives exhibited significant anti-inflammatory activities. Compound with fluoro substituents (7l and 8l) was found to be significantly more effective (P<0.01) anti-inflammatory agent as compared to other synthesized analogues. Based on anti-inflammatory data, compound 8l was selected for further in-vivo study. A simple, accurate, precise, rugged and economic HPLC method was developed and validated for estimation of compound 8l in serum using Indomethacin as an internal standard. The pharmacokinetic parameters were calculated by a non-compartment approach for the serum concentration of compound (8l) using software Kinetic (version 5.0). C_{max} and T_{max} for compound 8l were directly calculated by the standard non-compartmental analysis. C_{max}, T_{max} and T_{1/2} of compound 8l were found to be 52.54 µg/mL, 3 h and 4.36 respectively. Area under the time curve upto 24 h determined by linear trapezoidal rule was found to be 345.26 µg.h/mL. Area under the serum concentration time curve extrapolated to infinity was found to be 424.22 µg.h/mL and mean residence time was calculated and was found to be 7.63 h.



(Signature)
(Dr. R. O. Ganjiwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgaon (Meghe), Wardha

PC-11

✓ **QUALITY EVALUATION OF WATER IN WARDHA ZILLA**

Snehal S. Dixit*, Manisha P. Puranik

Department of Quality Assurance, Institute of Pharmaceutical Education and Research,
Wardha

ABSTRACT

Water is life and covers 70% of total surface of earth. It is transparent, tasteless, odorless and easily available. It contains number of minerals, such as Iron, Aluminium, Copper, Manganese, Zinc, Magnesium, Barium, Calcium, Silver, Selenium, Molybdenum, Boron, Nitrate, Sulphate, Sulphide, Fluoride, Chloride and Ammonia, which are important for growth and development of humans. It also contains heavy metals such as Arsenic, Mercury, Chromium, Cadmium, Lead and Nickel. The problem is that less than 1% of the water on the planet is readily available for drinking or for most agriculture purposes. Most of the water on earth, about 97%, is salt water stored in the oceans; and only 3% is fresh water. In the present work, water samples were collected from 13 different places of Wardha Zilla according to Government guidelines and analyzed in the laboratory for physical parameters, bacteriological analysis, chemical analysis and heavy metal analysis, further, proposed are some eco-friendly techniques for purification of water such as, Aeration, Boiling, Solar Disinfection, Sand Purification, Charcoal Purification and Baker's Yeast. From the study, we concluded that the health of water collected from 13 different places of Wardha Zilla was suitable for drinking purposes and the purification techniques proposed are simple, safe, eco-friendly, and economically cheap as compared to marketed purifiers whose reactivation cost is exorbitant.



(Signature)
(Dr. R. O. Ganjiwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgnour (Steghe), Wardha

PC-13

**CHARACTERIZATION OF POLYMORPHIC BEHAVIOUR OF DACLATASVIR
DIHYDROCHLORIDE USING INSTRUMENTAL TECHNIQUES**
Shraddha Shrikhande*, Lalit Rathi

Department of Quality Assurance, Institute of Pharmaceutical Education and Research,
Borgaon (Meghe), Wardha - 442001

ABSTRACT

This study aims with the formation and characterization of various solid-state forms of Daclatasvir dihydrochloride (DDL). The drug was subjected to polymorphic screening using different solvents to explore the possibility of existence of different solid forms and to investigate the factors affecting DDL polymorphic transformations. The polymorphs of DDL were prepared using methanol, ethanol, dimethyl formamide and dimethyl sulphoxide as crystallization solvents. The prepared polymorphs were characterized by differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD), scanning electron microscopy (SEM), fourier transform infrared (FTIR) spectroscopy and measurement of aqueous solubility and melting point; the effect of temperature and humidity was also investigated. Polymorphs prepared from various solvents exhibited differences in melting point when compared with the actual procured drug. The DSC thermograms for bulk drug showed single endothermic peak at 273.50oc while crystals recrystallized from ethanol and DMF exhibited broad endothermic peak at 97.08oc. X-ray diffractogram of crystals obtained from ethanol and DMF exhibited diffused peak when compared with bulk drug confirming the amorphous form of recrystallized polymorph. According to microscopic study, bulk drug exhibited spherical thin plate crystals while ethanolic crystals had rough surfaces of plates with irregularities in the crystals and crystals obtained from DMF showed aggregates of irregularly shaped particles. Thus the methods used for characterization enabled differentiation of DDL bulk drug and its prepared polymorph.



(Signature)
(Dr. R. O. Ganjivale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgaon (Meghe), Wardha

PC-17

FORMULATION AND OPTIMIZATION OF DEFLAZACORT ORAL FILMS USING BOX BEHNKEN DESIGN

Sunil P. Dewani, Ashish B. Budhrani*, Ritesh D. Akojwar

Institute of Pharmaceutical Education and Research, Borgaon (Meghe), Wardha

ABSTRACT

The objective of the investigation was to formulate oral disintegrating films loaded with Deflazacort (DZ) and to evaluate it under various parameters. Oral films of DZ were prepared, as suggested Box Behnken design, using HPMC as a polymer and Sodium starch glycolate (SSG), as disintegrant, in various proportions. The oral films were tailored using solvent casting method, and were subjected to evaluation parameters. Physicochemical parameters such as weight variation, folding endurance, surface pH, in-vitro disintegration and dissolution, SEM studies and accelerated stability studies were carried out. FTIR studies revealed that there was no drug-polymer interaction. The films disintegrated within 1 min and the fastest being disintegrated in 20 sec. The SEM images of the DZ strips revealed uniform distribution of drug in HPMC matrix, indicated by clear appearance. Based on all the evaluation parameters, batch containing 300 mg HPMC and 3% SSG, had revealed optimal performance, with drug release 95.87% in 5 minutes. The optimized formulation was found to be stable till three months under accelerated conditions. Results advocated use of HPMC as polymer and SSG as disintegrant in fast dissolving strip containing DZ.



(Signature)
(Dr. R. O. Ganjivale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgaon (Meghe), Wardha

1 of

PC-23

DESIGN, DEVELOPMENT AND EVALUATION OF pH RESPONSIVE MICROSPHERES CONTAINING CELECOXIB FOR COLON TARGETING BY USING BOX-BEHNKEN DESIGN

Akshay D. Gayakwad* and Sunil P. Dewani

Department of Pharmaceutics, Institute of Pharmaceutical Education and Research,
Wardha

ABSTRACT

Colon targeting is helpful for treatment of colonic diseases such as irritable bowel syndrome, ulcerative colitis, etc. Celecoxib, an anti-inflammatory drug was used as a model drug in current investigation. The pH responsive microsphere formulation may protect Celecoxib from degradation in upper GIT and thus by targeting to the colon, may reduce dosing frequency and provide prolonged drug release. Microspheres were prepared using solvent evaporation method by dispersing drug in the polymeric solution of Eudragit S100 and Ethyl cellulose, and then pouring this mixture into 1% span 80 and paraffin solution to obtain the microspheres. Box-Behnken design were used for optimization of various batches of microspheres. Microsphere were evaluated for particle size determination, drug content, entrapment efficiency, SEM, in vitro drug release and kinetics and accelerated stability study. Results showed that batch containing Eudragit S100 & Ethyl cellulose in 1:1 ratio, indicated maximum drug release ($97.69 \pm 0.037\%$) in 12hr and maximum drug entrapment efficiency (92.27%). The drug release followed Hixon Crowell kinetic model and indicated super-coiled polymer. Results suggested that pH responsive microsphere is a promising drug delivery system in the treatment of



(Signature)
(Dr. R. O. Ganjivale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgoo (Moghe), Wardha

PC-27

**DESIGN, DEVELOPMENT AND COMPARATIVE EVALUATION OF MEDICATED
ANTIDANDRUFF SHAMPOO WITH MARKETED FORMULATIONS**


Pranay D. Burle*, Lalit G. Rathi

Department of Quality Assurance, Institute of Pharmaceutical Education and Research,
Borgaon (M), Wardha

ABSTRACT

Hair is an important part of human body. The problems associated with it includes hair loss, dandruff, thinning of hair, dullness etc. Dandruff is small white pieces of dead skin in someone's hair or fallen from someone's hair. It is apparently caused by a fungus called *Malassezia restricta* and *Globosa malassezia*. Sertaconazole nitrate is a drug used in fungal infections of skin. The aim of the study is to prepare and determine the medicated shampoo's inhibitory effects on dandruff causing microorganism. Sertaconazole nitrate shampoo was prepared and evaluated in terms of physical (clarity and colour), performance (pH, % solid content, viscosity, dirt dispersion, cleaning, surface tension and foaming) and chemical characteristics (non-volatile alcohol soluble matter, active detergent content). All characteristics of all batches of shampoo were found in limit as specified in Indian standard. Stability study revealed that the formulated shampoo was stable for a prolong period of time as compared to marketed shampoo. The antifungal activity of shampoo was studied against selected fungal strain (*Mallassezia furfur*) using Sertaconazole as a positive control by cup plate diffusion method and was found to be effective against the selected fungal species. Hence Sertaconazole nitrate can be used as an anti-dand infections.




(Dr. R. O. Ganjwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgaon (M), Wardha

FORMULATION AND CHARACTERIZATION OF NATEGLINIDE CRYSTALLO CO-AGGLOMERATES

Vaishnav C. Dhote*, Lalit G. Rathi

Department of Quality Assurance, Institute of Pharmaceutical Education and Research,
Borgaon (M), Wardha

ABSTRACT

Crystallo-co-agglomeration (CCA) is agglomeration processes that transform crystalline drugs directly into compacted spherical form for improving flowability, solubility and compactability by size enlargement of low or high dose, poorly compressible drugs and combination of drugs with or without diluents. Nateglinide is an anti-hyperglycemic drug with poor dissolution and flow properties. The aim of study is to prepare CCA of Nateglinide with the objectives to develop pharmaceutically equivalent, stable, and quality improved agglomerate of Nateglinide with enhanced wettability, solubility, dissolution rate, flow properties and mechanical properties using hydrophilic polymers. CCA of Nateglinide were prepared using three solvent system i.e good solvent, bad solvent and bridging solvent comprising of methanol-water-dichloromethane. Agglomeration was carried out using different concentrations



R. O. Ganjivale
(Dr. R. O. Ganjivale)

Principal
PRINCIPAL

Institute of Pharmaceutical Education & Research
Borgaon (M), Wardha

PC-40
**FORMULATION AND EVALUATION OF ENTERIC COATED EXTENDED
RELEASE TABLET**

Kajal D. Chaudhari*, Sunil P. Dewani, Chetan D. Kundojwar

Department of Pharmaceutics, Institute of Pharmaceutical Education & Research, Wardha

ABSTRACT

Extended release drug formulations are intended to continuously release medication over a prolonged period, after a single dose. Erythromycin is a slightly soluble and weakly acidic drug which degrades in acidic environment of stomach and leads to therapeutic inefficacy. The objective of present study is to formulate and evaluate enteric-coated extended release Erythromycin tablets with an aim to improve the stability of the drug. Erythromycin has low solubility so inclusion complex with beta Cyclodextrin was formulated to increase solubility of erythromycin which was evaluated using FTIR, XRD and DSC. Preformulation study were conducted viz; bulk density, tapped density, angle of repose, compressibility index and Hausners' ratio. Core tablet was formulated by direct compression method using HPMC K15M as an extended release polymer in different concentration. Formulation containing 1:0.75(C1) ratios was selected as optimized formulation, as it was capable of releasing drug up to 10hrs. Batch CE2 was selected as an optimized batch on the basis of lag time and in vitro release i.e 99.27%. The stability studies were carried out on optimized formulation (CE2) at 4± 2°C and 75± 5% R.H. for 3months. No significant changes in drug release were obtained and hence it was concluded that the optimized formulation (CE2) was stable.



R. O. Ganjivale
(Dr. R. O. Ganjivale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgnour (Moghe), Wardha

PC-42

IMPROVEMENT IN SOLUBILITY AND DISSOLUTION BEHAVIOUR OF A POORLY WATER SOLUBLE DRUG CILNIDIPINE USING SOLUPLUS BY SOLID DISPERSION TECHNIQUE


Komal K. Kharabe*, Shagufta A. Khan

Department of Pharmaceutics, Institute of Pharmaceutical Education & Research, Wardha

Abstract

Solid dispersion is one of the most effective approaches to improve the solubility and dissolution rate and hence, the bioavailability of poorly water-soluble drug. Cilnidipine is a calcium channel blocker use to treat hypertension. The aim of present investigation is to formulate solid dispersion of slightly water soluble drug (Cilnidipine) using water soluble polymer (Soluplus). The solid dispersion is to be evaluated for the changes in solubility and dissolution rate. Solid dispersion was prepared by solvent evaporation method and evaluated for the solubility and dissolution behavior of the drug in solid dispersion. Student t-test is used for comparing % drug dissolution rate and saturated solubility of solid dispersion with pure drug. It indicates that P value is less than 0.05 that means increase in % cumulative drug release was significant. The P value of solid dispersion with pure drug in acid buffer pH 1.2 was insignificant (0.3543) and in phosphate buffer pH 6.8 (0.0112). The solid dispersion of Cilnidipine in the ratio 1:1 showed 4, 3.23 and 4 fold increase in solubility in water, pH 1.2 buffer and pH 6.8 buffer respectively. Thus, it was concluded that soluplus overcomes the dissolution rate limited absorption problem of Cilnidipine and improves its bioavailability.




(Dr. R. O. Ganjiwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgoun (Moghe), Wardha

stability.

PC-59

**FORMULATION DEVELOPMENT OF TOPICAL GEL LOADED WITH NANOSPONGES
OF ANTI FUNGAL DRUG**

Vaishnavi S. Vairagade*, S.P. Dewani

Department of Pharmaceutics, Institute of Pharmaceutical Education and Research,
Wardha

ABSTRACT

Ketoconazole is Antifungal drug often used in the treatment of fungal infection of skin such as athletes foot, jock itch, ringworm, candidiasis, seborrhea. It has pH dependent solubility and permeability. The drug has a half-life of 1 to 2 hours. Because of its short biological half life the drug has to be administered frequently. Furthermore oral ketoconazole causes irritation in gastric mucosal membrane and posses a bitter taste. The present work at designing novel nanospheres as carriers for topical delivery of ketoconazole which minimizes its gastro intestinal side effects and provides consistent drug levels at application site for longer period of time. Methodology included a) The compatibility parameters were studied using IR method. b) The nanospheres were characterized for loading efficiency, entrapment efficiency, particle size and in vitro drug release. c) The gel formulations were evaluated for % drug content, pH, viscosity, spreadability and in vitro diffusion study. The optimized formulation was evaluated for percent cumulative drug release after 24 hours. The changes in drug release were obtained hence it was optimized.



(Dr. R. O. Ganjiwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgaon (Ategha), Wardha

PH-14

**ANALGESIC AND ANTI-INFLAMMATORY POTENCY OF FLAVONOIDS EXTRACT
FROM *RICINUS COMMUNIS***

Rushali C. Bhaimare*, Hemlata Joshi, Angad M. Patole, Roul Jyotiranjn

Department of Pharmacology, Institute of Pharmaceutical Education and Research,
Wardha

ABSTRACT

The aim of present investigation was evaluation of analgesic and anti-inflammatory activity of flavonoidal extracts from *Ricinus communis*. The *Ricinus communis* or castor plant has high traditional and medicinal value for maintain the diseasefree healthy life. The present study was conducted to evaluate the analgesic and anti-inflammatory effect of flavonoidal extracts of *Ricinus communis* leaves in Albino rats. Carageenan induced paw edema was employed to evaluate antiinflammatory activity while analgesic activity was investigated by using hot plate method. In the selected model careggenan was used as inflammation inducing agent. It was found that flavonoidal extract of leaves of *Ricinus communis* (100mg/kg and 150 mg/kg) has significant analgesic and anti-inflammatory activity whereas the combination drug (std + test) provides more potent results than 100mg/kg and 150 mg/kg alone. On the basis of the results of the current study, it is concluded that the flavonoidal extracts of leaves of *Ricinus communis* displays considerable potency in analgesic and anti-inflammatory activity.



(Signature)
(Dr. R. O. Ganjiwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgon (Moghe), Wardha

Both can have lasting consequences on health – especially for the sick persons. Overall, the question is which damages and hazards exist and what risks can be derived from them for the users, and possibly for their environment. For any use of health apps, hazards must be eliminated and risks minimised to reduce potential damage. Perhaps some individuals should not be encouraged to use apps at all, including those who worry excessively about their health, and those unwilling to confer with qualified health professionals able to validate app findings. Most individuals, however, should be encouraged to self-manage. Make changes without communicating further with any health professionals is on the high risk. The biggest risk for covered entities is that the app "could be used as a public-facing gateway by hackers to impermissibly obtain protected health information.

PH-27

PARADIGM SHIFT IN ONCOLOGY: TARGETING THE IMMUNE SYSTEM RATHER THAN CANCER CELLS

A. S. Tiwari*

SGSPS Institute of Pharmacy, Akola

ABSTRACT

Cancer immunotherapy uses the immune system and its component to mount an anti-tumour response. The two main area of it administration of monoclonal antibody and cytokine and adaptive cell transfer. The clinical benefits obtained with rituximab in the treatment of CD20+ B-cell malignancies and of imatinib in the treatment of Phi+ leukaemias have opened a new era in oncology, transforming the concepts of tumour-targeted therapies and personalised medicine into reality. Since then, many tumour-targeted monoclonal antibodies and tyrosine kinase inhibitors have been approved for the treatment of cancers. Compared to conventional chemotherapies, these new drugs have more specificity against cancer cells and less systemic toxicities. However, like conventional chemotherapies, they often provide limited therapeutic benefits with short-lasting tumour responses as the vast majority of cancers become resistant to these drugs over time. Recently, a paradigm shift has been brought to the clinic with drugs targeting immune cells rather than cancer cells with the aim of stimulating the anti-tumour immune response of patients against their own cancer. Immunomodulatory drugs such as anti-CTLA4 and anti-PD-1 have generated long-lasting tumour responses when used as single agent in patients.

PH-28

✓ PHARMACOLOGICAL EFFECTS OF NETTLE ROOT EXTRACT (*Urtica-dioica*) ON BENIGN PROSTATIC HYPERPLASIA

Vedant Pawnikar*, Shital Meghare, Kajal Wairagade, Mohan Mangtani, Angad Patole

Institute of Pharmaceutical Education and Research, RTMNU University, Nagpur, Maharashtra

ABSTRACT

Benign Prostatic Hyperplasia (BPH) is the nonmalignant enlargement of the prostate gland. It is clinically demonstrated as lower urinary tract symptoms (LUTS) consisting of irritative and obstructive symptoms. The frequency of LUTS increases due to BPH with increasing age. Aim was to evaluate effect of Nettle Root Extract on Benign Prostatic Hyperplasia (BPH) in rats. Testosterone (10 mg/kg i.m.) was used as inducing agent and Finasteride (10mg/kg p.o.) was used as the standard drug. The various groups of animals received Aq. Nettle Root Extract alone (50 mg/kg), Alc. Nettle Root Extract alone (50 mg/kg), Aq. Nettle Root Extract (25 mg/kg) & Finasteride (5 mg/kg) in combination and Alc. Nettle Root Extract (50 mg/kg) & Finasteride (5 mg/kg) in combination respectively once daily per orally for 28 days and various parameters of BPH viz. body weight, prostate weight, determination of hormones and histopathology of prostate were recorded. The present study revealed that Alc. Nettle Root Extract & Finasteride showed significant decrease in body weight, prostate weight, increase in prolactin level as compared to control. There is sufficient evidence that Nettle Root Extract alone has potential effect on various symptoms of BPH.



(Dr. R. O. Ganjivale)
Principal

PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgnour (Meghe), Wardha

PH-31

**A COMPREHENSIVE STUDY ON PHARMACOLOGICAL EFFECTS OF GALLIC ACID
AGAINST ALZHEIMER'S DISEASE IN ALBINO RATS**

Shital S. Meghare*, Vedant V. Pawnikar, Angad M. Patole

Institute of Pharmaceutical Education and Research, Borgaon (Meghe), Wardha,
Maharashtra, India

ABSTRACT

Alzheimer's disease (AD) is defined as prefrontal dementia, is a progressive, age dependent neurodegenerative disorder of the cortex and hippocampus, eventually leading to cognitive impairment of the brain. Gallic acid (GA) a natural polyphenolic compound found abundantly in grapes, different berries and wine may hold potential compound for intervention of AD due to its ROS scavenging, anticholinesterase and lipid peroxidation prevention property. To investigate the effect of gallic acid in rodent model of AD. Scopolamine (0.5 mg/kg) was administered intraperitoneally 30 minutes before the start of the experiment. The effect of gallic acid (10, 20, 40 mg/kg) was observed on the cholinergic system in young

young



(Signature)
(Dr. R. O. Ganjivale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgaon (Meghe), Wardha

PH-32

**✓ PHARMACOLOGICAL SCREENING OF POLYHERBAL FORMULATION ON
POLYCYSTIC OVARIAN SYNDROME IN FEMALE ALBINO RATS.**

Kajal R. Wairagade*, Achal D. Ghatе, Angad M. Patole, R. O. Ganjiwale
Institute Of Pharmaceutical Education And Research Borgaon (Meghe) Wardha

ABSTRACT

Polycystic ovary syndrome is highly prevalent endocrine disorder. Letrozole inhibit the aromatase enzyme by binding to the subunit of cytochrome P450, which results in abnormal follicular development and polycystic ovarian syndrome. Actifem helps to balance the hormone profile, it is able to decrease the number of cysts and development of healthy follicle along with formation of corpus luteum. Body weight, biochemical parameters and hormonal profile were used for examination of letrozole induced PCOS in rats. Experimental groups consist of five groups. Except normal group all rats were once daily administered with letrozole 1mg/kg p.o. for 21 days to induce PCOS. The standard group received 1mg/kg p.o. of clomiphene citrate while the treatment groups were treated with 3.5ml/kg and 7ml/kg p.o. respectively with Actifem for 15 days after PCOS induction. Body weight, biochemical parameter includes lipid profile and biomarkers of ovarian function, i.e serum testosterone and serum estradiol were estimated on post induction day and at the end of the treatment i.e on 22nd and 38th day respectively. The administration of letrozole led to increase in body weight, abnormality in lipid and serum sex steroid profile. Actifem was able to exert its profitable after effect by bringing back parameters to normal and disappearance of ovarian cyst. Actifem showed a gainful outcome in letrozole induced PCOS in female rats. It decreased the obesity and reduced the level of serum testosterone and estradiol (hyperandrogenism) which helps to prevent infertility



Analgesic activity superior to that of the standards, Ibuprofen. These compounds also exhibited significant Anti-microbial activity comparable to that of sulphonamide.

PCH-04

A LINEAR QSAR MODEL FOR PREDICTING THE INHIBITION OF CETP ENZYME BY ARYLBENZOXAZOLE DERIVATIVES AND ACTIVE SITE CHARACTERIZATION BY DOCKING STUDIES

P.G. Swami*, G.R. Kadam, S.J. Wadher, R.O. Ganjiwale

ABSTRACT

Cholesteryl ester transfer protein [CETP] is a plasma glycoprotein which plays an important role in reverse cholesterol transport and maintenance of cholesterol homeostasis. It facilitates the transfer of cholesteryl esters from the atheroprotective HDL to the proatherogenic LDL and VLDL. Inhibition of CETP activity leads to increased HDL-cholesterol. High density lipoprotein [HDL-C] concentration in the blood is independently and inversely associated with an increased risk of coronary heart disease. CETP has become a novel strategy for raising HDL-C in humans. A series of 2-Arylbenzoxazole derivatives recently discovered as CETP inhibitors were studied. Linear QSAR models were built using multiple linear regression of 30 arylbenzoxazole derivatives to probe their CETP inhibition activity. The binding conformations of arylbenzoxazole derivatives were determined and predicted. These results demonstrated the power of combining docking / the probable binding conformations of compounds at the target.



R. O. Ganjiwale
(Dr. R. O. Ganjiwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Dorgaon (Stephe), Wardha

Priyadarshini J L College of Pharmacy, Nagpur

ABSTRACT

Standardisation of leaf of *Guazuma tomentosa* is carried out to establish its macroscopic and microscopic characters and its quantitative physicochemical standards. Total ash, water soluble ash, acid insoluble ash, swelling index, extractive value (ethyl acetate, dichloromethane, alcohol and water soluble extractive value both hot and cold) were determined for physicochemical evaluations. Preliminary phytochemical screening was done to detect the presence and absence of phytoconstituents. Thin layer chromatography was carried out which play important role in assuring quality of crude drug. The drug can be identified on the basis of morphology and microscopic characters. Phytochemical screening revealed that leaf extract contain alkaloids, carbohydrate, phytosterol, resin, flavanoids, tannins, diterpenes and protein. TLC chromatogram and different physicochemical standard has been developed. The present study on pharmacognostic standardisation, physicochemical evaluation of *Guazuma tomentosa* leaf might be useful to supplement information in regard to its identification parameters assumed significantly in the way of acceptability of herbal drugs in present scenario.

PG-16**EVALUATION OF FREE RADICAL SCAVENGING PROPERTIES OF *BOMBAX CEIBA* THORNS****Pallavi B. Hatwar*, Shailju G. Gurunani**

Priyadarshini J.L. College of Pharmacy, Hingna Road, Nagpur

ABSTRACT

Bombax ceiba also known as kantesavar & red cotton silk has various medicinal properties like Astringent, Antiacne, Antipyretic, cardiogenic in the traditional system of medicine such as Ayurveda, Siddha and Unani. The present study was performed to determine the yield of extract, qualitative, quantitative analysis and antioxidant activity of the crude extract of *Bombax ceiba*. The qualitative phytochemical screening of crude extract shows the presence of Steroids, Carbohydrate, Tannins, Flavonoids. Total phenolic content was estimated by Folin ciocalteu method and was found to be 216µg/mg & 133.3µg/mg gallic acid equivalent in acetone extract & methanol extract. Total flavonoid content was estimated by Aluminium chloride colorimetric method and was found to be 3.62µg/mg & 3.5µg/mg rutin equivalent in acetone extract & methanol extract. Total carbohydrate content was found to be 0.137µg/mg & 0.3µg/mg glucose in acetone extract & methanol extract respectively. The various extract of *Bombax ceiba* thorns shows significant antioxidant activity by DPPH radical scavenging method. Ascorbic acid used as positive control showed 92.48% scavenging activity which was followed by PEEBC, AEBC, WEBC & MEBC showed 54.18%, 47.47%, 44.95% & 43.25% activity respectively.

PG-17**EFFECTS OF DIFFERENT HOMEOPATHIC POTENCIES OF *GYMNEMA SYLVESTRE* IN TREATMENT OF ALLOXAN INDUCED DIABETES****S. V. Padhare*, M. V. Navadkar, P. R. Itankar, R. O. Ganjiwale**

Institute of Pharmaceutical Education and Research, Borgoan (Meghe), Wardha

ABSTRACT

This study was design to evaluate the effect of homeopathic preparation of *Gymnema sylvestre* R Br. (family: Asclepiadaceae) mother tincture (MT), 3x & 10x potencies on diabetic albino mice of either sex. Diabetes was induced by intraperitoneal injection of alloxan monohydrate (150 mg/kg body weight) administration. Mice were divided into 6 groups (n=6). Group 1 & 2 were kept normal control and diabetic control respectively whereas groups 3-5 consists of diabetic mice treated with different doses of *G. sylvestre* MT, 3X and 10 X potencies for 21 days. Insulin (4IU/kg; s. c.) was used as standard. Blood glucose levels were tested by glucose test strips. The fasting blood glucose levels (12 h) and body weight were recorded. The results of the study showed that homeopathic potencies of *G. sylvestre* t



(Dr. R. O. Ganjiwale)
Principal

PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgoan (Meghe), Wardha

PC-05

PREPARATION OF FLOATING MUCOADHESIVE TABLET OF A DRUG HAVING NARROW ABSORPTION IN THE GASTROINTESTINAL TRACT

Rupali D. Deshmukh*, Shafgupta Khan

Department of Pharmaceutics, Institute of Pharmaceutical Education and Research, Borgaon (Meghe), Wardha

ABSTRACT

Residronate sodium shows the narrow absorption window and short half life in a gastrointestinal tract therefore has low bioavailability. Therefore in the present investigation floating and mucoadhesive tablets were prepared of residronate sodium by using different ratios of fenugreek gum and guar gum. Sodium bicarbonate was used as a gas-former and microcrystalline cellulose as diluents. Tablets were characterized for floating lag time, floating duration, swelling behavior and drug release. Results showed With the increase in the ratio of guar gum: fenugreek gum, swelling increases and decreases the drug release. Floating lag time decreased with by increasing concentration of MCC, floating lag time of one minute was observed with MCC at the 25%w/w. Rapid achievement of floating and prolonged floating and drug release was obtained for 12h within one min.

PC-06

DEVELOPMENT AND EVALUATION OF TOPICAL FORMULATION FOR SKIN WHITENING CONTAINING HERBAL INGREDIENTS

Vijayshri V.Rokde*, Rajayshri Dongarwar, Ujwala Mahajan

Dadasaheb Balpande Co



(Signature)
(Dr. R. O. Ganjivale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgaon (Meghe), Wardha

A Concise Handbook of **PHARMACOLOGY-I**

First Edition

An Essential Guide for B. Pharmacy Students
(Designed as per PCI Syllabus)

Dr. Rajendra O. Ganjiwale
Mr. Jyotiranjjan T. Roul



P.R. S



Rajendra O. Ganjiwale
(Dr. R. O. Ganjiwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgou (Meghe), Wardha

A Concise Handbook of Pharmacology-I

First Edition: May 2019

ISBN: 978-81-941397-0-6

Copyright ©: Authors

No part of this book shall be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or by any information retrieval system without written permission of the publisher.

Every effort has been made to avoid errors or omissions in this publication. In spite of this, errors may have crept in. Any mistake, error or discrepancy so noted and shall be brought to our notice shall be taken care of in the next edition. It is notified that neither the publisher nor the authors or seller shall be responsible for any damage or loss of action to any one, of any kind, in any manner, thereform.

Published By:


PR Scientific Publication

Plot No: 2163/3983, Amarendra Colony, College Road, Nayagarh,
Odisha-752069

Email: prscientificpublication@gmail.com

Price: Rs. 199.00




(Dr. R. O. Ganjivale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgnon (Meghe), Wardha

A Concise Handbook of

PHARMACOLOGY-II

First Edition

An Essential Guide for B. Pharmacy Students
(Designed as per PCI Syllabus)

Dr. Rajendra O. Ganjiwale
Mr. Jyotiranjana T. Roul



P.R.S.



Rajendra O. Ganjiwale
(Dr. R. O. Ganjiwale)
Principal
PRINCIPAS
Institute of Pharmaceutical Education & Research
Borguon (Moghe), Wardha

A Concise Handbook of Pharmacology-II

First Edition: May 2019

ISBN: 978-81-941397-1-3

Copyright ©: Authors

No part of this book shall be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or by any information retrieval system without written permission of the publisher.

Every effort has been made to avoid errors or omissions in this publication. In spite of this, errors may have crept in. Any mistake, error or discrepancy so noted and shall be brought to our notice shall be taken care of in the next edition. It is notified that neither the publisher nor the authors or seller shall be responsible for any damage or loss of action to any one, of any kind, in any manner, thereform.

Published By:

PR Scientific Publication

Plot No: 2163/3983, Amarendra Colony, College Road, Nayagarh,
Odisha-752069

Email: prscientificpublication@gmail.com

Price: Rs. 249.00



Dr. R. O. Ganjiwale
(Dr. R. O. Ganjiwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgoo (Asteph), Wardha

FOCUS ON
PHARMACOLOGY & TOXICOLOGY

(An Essential Guide for D. Pharmacy Students)

1st Edition



Dr. Bhushankumar S. Sathe
Mr. Jyotiranjana T. Roul
Mr. Milind N. Bhojar



(Signature)
(Dr. R. O. Ganjiwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgoo (Mehga), Wardha



P.R. Scientific Publication

FOCUS ON

PHARMACOLOGY & TOXICOLOGY

First Edition: July 2019

ISBN: 978-81-941397-3-7

Copyright ©: Authors

No part of this book shall be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or by any information retrieval system without written permission of the publisher.

Every effort has been made to avoid errors or omissions in this publication. In spite of this, errors may have crept in. Any mistake, error or discrepancy so noted and shall be brought to our notice shall be taken care of in the next edition. It is notified that neither the publisher nor the authors or seller shall be responsible for any damage or loss of action to any one, of any kind, in any manner, therefore.

Published By:


PR Scientific Publication

Plot No: 2163/3983, Amarendra Colony, College Road, Nayagarh, Odisha-752069

Email: prscientificpublication@gmail.com

Price: Rs. 200.00




(Dr. R. O. Ganjwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgou (Steghe), Wardha

CONTENTS


Chapter	Topic	Page
1	Introduction to Pharmacology	1-41
2	Drugs acting on CNS	42-78
3	Drugs acting on ANS	79-106
4	Drugs acting on CVS	107-140
5	Drugs acting on Respiratory system	141-146
6	Autacoids	147-154
7	Hormones	155-190
8	Drugs acting on Digestive system	191-195
9	Pharmacology Of Laxatives And Cathartics	196-199
10	Chemotherapy	200-240
11	Some Important Questions	241-250



(Signature)
(Dr. R. O. Ganjiwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgun (Moghe), Wardha

Nanobiotechnology in Neurodegenerative Diseases




(Dr. R. O. Ganjivale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgnour (Meghe), Wardha

Mahendra Rai • Alka Yadav
Editors

Nanobiotechnology in Neurodegenerative Diseases



R. O. Ganjiwale
(Dr. R. O. Ganjiwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgun (Ategho), Wardha

 Springer

Editors

Mahendra Rai
Nanobiotechnology Laboratory
Department of Biotechnology
SGB Amravati University
Amravati, Maharashtra, India

Department of Chemistry
Federal University of Piauí
Teresina, Piauí, Brazil

Alka Yadav
Nanobiotechnology Laboratory
Department of Biotechnology
SGB Amravati University
Amravati, Maharashtra, India

ISBN 978-3-030-30929-9

ISBN 978-3-030-30930-5 (eBook)

<https://doi.org/10.1007/978-3-030-30930-5>

© Springer Nature Switzerland AG 2019


This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Switzerland AG
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland





(Dr. R. O. Ganjwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borguon (Moghe), Wardha

Preface

Neurodegenerative (ND) diseases comprise a range of conditions that primarily affect the neurons in the human brain. Neurons are the building blocks of our brain, which normally don't reproduce or replace themselves if they get damaged. ND diseases include Parkinson's disease, Alzheimer's disease, and Huntington's disease. The most problematic feature of ND diseases is that they are incurable and result in the progressive degeneration of neuron cells. The major cause of ND diseases is related to genetic mutation; apart from this, protein misfolding, DNA damage, apoptosis, mitochondrial dysfunction, and programmed cell death are the other causes of ND diseases. A number of ND disorders have been thoroughly examined, but successful, early diagnoses and treatment have been limited. The key reason for this is the blood–brain barrier that prevents the penetration of the majority of drugs and agents to effectively treat the disorders.

Nanobiotechnology as an emerging tool has the potential to play a pivotal role to improve the understanding and treatment of neurodegenerative diseases. Different types of nanomaterials can be implemented for diagnosis, drug delivery, and treatment of neurodegenerative diseases. Engineered nanoparticles are materials with dimension 1–100 nm. Metal nanoparticles showcase an innovative and promising approach to potentially solve problems related to ND diseases. Due to their smaller size, nanoparticles are able to interact with biological systems at a molecular level. The smaller sized nanoparticles can also cross the blood–brain barrier. Hence, the physical, chemical, and biological properties of nanoparticles can be utilized for diagnosis, therapy, tissue engineering, regeneration, and drug delivery. Similarly, exosomes are also evolving as therapeutic nanobiomaterials for drug delivery in neurodegenerative diseases as they have the ability to cross the blood–brain barrier. Moreover, in recent years, the field of nanobiosensors is growing quickly, and with the help of nanotechnology, it is possible to develop higher sensitivity for nanobiosensors. This area of research is attracting scientists in general and medical experts in particular. In this book, a brief overview of the different ND diseases and advancements in nanobiotechnology for the treatment of ND is discussed by eminent contributors.





(Dr. R. O. Ganjivale)
Principal
PRINCIPAB
Institute of Pharmaceutical Education & Research
Borgun (Steghe), Wardha

This book is beneficial for a wide range of readers including nanotechnologists, biotechnologists, pharmacists, medical professionals, bioengineers, biochemists, and researchers who are involved in the field of research on neurodegenerative diseases.

Amravati, Maharashtra, India

Mahendra Rai
Alka Yadav





(Dr. R. O. Ganjiwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgun (Moghe), Wardha

Contents


1 Neurodegenerative Diseases: The Real Problem and Nanobiotechnological Solutions	1
Mahendra Rai, Alka Yadav, Avinsh P. Ingle, Anatoly Reshetilov, María José Blanco-Prieto, and Chistiane M. Feitosa	
2 Nanotechnology at the Rescue of Neurodegenerative Diseases: Tools for Early Diagnostic	19
Jean-Michel Rabanel, Morgane Perrotte, and Charles Ramassamy	
3 The Role of Nanomedicine in the Treatment of Neurodegenerative Disorders	49
Syed Tazib Rahaman	
4 Nanobiotechnology in Neurodegenerative Diseases.	65
Josef Jampílek, Katarína Král'ová, Petr Novák, and Michal Novák	
5 Application of Mycogenic Nanoparticles Against Neurodegenerative Diseases	139
Jhonatas Rodrigues Barbosa, Maurício Madson dos Santos Freitas, Luiza Helena da Silva Martins, Andrea Komesu, Alessandra Santos Lopes, Raul Nunes de Carvalho Junior, and Mahendra Rai	
6 Nanotechnology-Mediated Nose-to-Brain Drug Delivery for Neurodegenerative Disorders.	163
Chandrakantsing V. Pardeshi, Veena S. Belgamwar, and Sanjay J. Surana	
7 Nanobiotechnology in Parkinson's Disease	177
Pablo Vicente Torres-Ortega, Iván Martínez-Valbuena, Gloria Martí-Andrés, Amira Sayed Hanafy, María Rosario Luquin, Elisa Garbayo, and María José Blanco-Prieto	




(Dr. R. O. Ganjivale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgunr (Moghe), Wardha

8	Selenium Nanoparticles as Therapeutic Agents in Neurodegenerative Diseases	209
	Shanmugam Rajeshkumar, Lakshmanan Ganesh, and Jayakodi Santhoshkumar	
9	Role of Supermagnetic Nanoparticles in Alzheimer Disease	225
	Shanmugam Rajeshkumar, Devaraj Ezhilarasan, Napaphol Puyathron, and Thangavelu Lakshmi	
10	Nanomedicines for Improved Antiretroviral Therapy in Neuro-AIDS	241
	Aarti Belgamwar, Shagufta Khan, and Pramod Yeole	
11	Nanocarrier-Mediated Drug Delivery Systems for Neurodegenerative Diseases	267
	Sathika G. G. Arachchige, Ryan Rienzie, and Nadeesh M. Adassooriya	
12	Gold Nanoparticles in Diagnosis and Treatment of Alzheimer's Disease	289
	Senthilkumar Sivanesan and Shanmugam Rajeshkumar	
13	Nanolipidic Carriers as Potential Drug Delivery Vehicles in Alzheimer's Disease	307
	Sushama Talegaonkar, Namrata Gautam, Venu Varshney, Sandeep Kumar Sharma, and Arundhati Bhattacharyya	
14	Curcumin and Its Nanoformulations as Therapeutic for Alzheimer's Disease	343
	Vandita Kakkar, Parina Kumari, Suneera Adlakha, and Indu Pal Kaur	
15	Nanopharmaceuticals for the Improved Treatment of Cerebral Stroke	369
	Shagufta Khan, Aarti Belgamwar, and Pramod Yeole	
	Index	387




 (Dr. R. O. Ganjiwale)
 Principal
 PRINCIPAL
 Institute of Pharmaceutical Education & Research
 Borgnour (Moghe), Wardha

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Nanopharmaceuticals for the Improved Treatment of Cerebral Stroke

Nanobiotechnology in Neurodegenerative Diseases pp 369-385 | Cite as

- Shagufta Khan (1)
- Aarti Belgamwar (2)
- Pramod Yeole (3)

1. Institute of Pharmaceutical Education and Research, , Wardha, India
2. SVKM's Institute of Pharmacy, , Dhule, India
3. Dr. Babasaheb Ambedkar Marathwada University, , Aurangabad, India

Chapter

First Online: 03 December 2019

- 65 Downloads

Abstract

Stroke remains the leading cause of death and disability across the globe. However, there is a dearth of effective therapy for its treatment. Over the past decade, use of nanomedicine has gained overwhelming interest for the treatment of cerebral stroke due to the constant failure of the conventional treatment. The most widely investigated nanocarriers include neuroprotective agents loaded on functionalized liposomes and polymeric nanoparticles for targeted delivery to the brain, metal oxide nanoparticles, carbon nanotubes, dendrimers, and scaffolds. This chapter will focus on the investigations undertaken hitherto on different types of nanocarriers for delivery of therapeutic agents for the treatment of stroke.

Keywords

Nanopharmaceuticals Cerebral stroke Nanomedicine Liposomes Nanocarriers Neuroprotective

Nomenclature



R. O. Ganjiwale
(Dr. R. O. Ganjiwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgun (Moghe), Wardha

Springer Nature is making Coronavirus research free. [View research](#) | [View latest news](#) | [Sign up for updates](#)

Nanomedicines for Improved Antiretroviral Therapy in Neuro-AIDS

Nanobiotechnology in Neurodegenerative Diseases pp 241-266 | Cite as

- Aarti Belgamwar (1)
- Shagufta Khan (2)
- Pramod Yeole (3)

1. SVKM's Institute of Pharmacy, , Dhule, India
2. Institute of Pharmaceutical Education and Research, Borgaon (Meghe), , Wardha, India
3. Dr. Babasaheb Ambedkar Marathwada University, , Aurangabad, India

Chapter

First Online: 03 December 2019

- 64 Downloads

Abstract

Human immunodeficiency virus is neurotropic which invades the central nervous system (CNS) in early course of systemic infection and makes the CNS an important dominant reservoir with the capacity to supply virus in low/undetectable viremia. Neuro-AIDS is the major upcoming issue among long-term seropositive survivors as a consequence of incompetence of antiretroviral in complete eradication of HIV from the CNS.

Justification behind the low CNS concentration of antiretroviral is anatomical barrier and physicochemical properties of antiretrovirals. Some unmet needs in neuro-AIDS treatment are simplified CNS-targeted treatment regimen and disease-modifying therapies. Target-specific, safe, and controllable nanomedicines have been extensively studied, with particular success, to overcome the natural barriers to the antiretroviral drug delivery posed by the CNS anatomy, histology, and physiology. This chapter insight on current understanding of neuro-AIDS and the pathological mechanisms involved several limitations to the eradication of latent reservoirs and approaches to circumvent these limitations by state-of-the-art nanomedicines.

Keywords




(Dr. R. O. Ganjivale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgaon (Meghe), Wardha

AIMST International Pharmacy Conference (AIPC) 2019

Challenges and Opportunities
in Pharmaceutical Sciences, Technology and Practice

30 November - 1 December 2019




(Dr. R. O. Ganjivale)
Principal
PRINCIPAB
Institute of Pharmaceutical Education & Research
Borgunur (Moghe), Wardha

AIMST International Pharmacy Conference 2019

Challenges and Opportunities in Pharmaceutical Sciences, Technology and Practice

Organized by

Faculty of Pharmacy, AIMST University

In collaboration with

MPS Kedah/Perlis Area, Malaysia


and

Indian Pharmacy Graduates' Association (IPGA), India

30 November - 1 December 2019

BOOK OF ABSTRACTS




(Dr. R. O. Ganjivale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgaon (Stephe), Wardha



SEMELING, KEDAH, MALAYSIA

Development and *in-vivo* evaluation of intranasal dolutegravir sodium nanoparticles for brain targeting in neuro-AIDS

Aarti Belgamwar^{1,2*}, Shagufta Khan²

¹ SVKM's Institute of Pharmacy, Dhule, Maharashtra, India

² Institute of Pharmaceutical Education and Research, Wardha, Maharashtra, India

*Email: aartibelgamwar@yahoo.co.in

Background: Neuro-AIDS is a major upcoming issue amongst long term HIV seropositive survivors as a consequence of insufficient antiretrovirals (ARVs) CNS concentration. Dolutegravir sodium (DTG) is HIV integrase strand transfer inhibitor demonstrated impressive antiviral efficacy with limited access in the CNS on oral administration. **Objective:** The present investigation was focused to enhance the CNS bioavailability of dolutegravir sodium by delivering intranasal nanoparticles. **Material and methods:** Dolutegravir loaded nanoparticles (DTG-NPs) were prepared by cross-linking hydroxypropyl- β -cyclodextrin (HP β CD) with diphenyl carbonate to enhance its CNS uptake. NPs were characterized for various parameters like size, drug loading, *in vitro* release, safety and CNS uptake. **Conclusion:** Spherical shaped nanoparticles



(Dr. R. O. Ganjivale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgoo (Moghe), Wardha

1:4.16

Intranasal gelling mucoadhesive microspheres of carboxymethyl fenugreek gum and chitosan for improving bioavailability of gentamicin

Shagufta Khan*, Shirish Chawte

*Institute of Pharmaceutical Education and Research,
(Borgaon) Meghe, Wardha, Maharashtra, INDIA*

*Email: shaguftakhan17@rediffmail.com

Background: Gentamicin a broad spectrum aminoglycoside antibiotic, is very polar therefore, it is not absorbed through GIT. It is active against broad category of microorganisms but presently administered by parenteral route only. A non-invasive alternative route which can improve its bioavailability is highly desirable. **Objective:** The present study was aimed to improve bioavailability of gentamicin by intranasal delivery via gelling mucoadhesive microspheres prepared from a novel polymer carboxymethyl fenugreek gum (CMFG). **Material and methods:** CMFG and chitosan were used for preparation of microspheres. CMFG was synthesized by treating fenugreek gum extracted from seeds with mono-chloroacetic acid. The prepared CMFG was characterized for degree of substitution, viscosity, FTIR spectroscopy and Differential Scanning Calorimetry. Microspheres were formulated by single emulsion technique using different ratios of CMFG and chitosan and gelation of internal phase using tripolyphosphate (TPP). The microspheres were evaluated for drug content, entrapment efficiency, surface area, permeation rate, particle size, release, and stability.



(Dr. R. O. Ganjiwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgaon (Meghe), Wardha

TPS "Textbook"


Technical Pharmacy Series

Strictly Based On PCI Syllabus



PATHOPHYSIOLOGY

SECOND SEM. B. PHARM



Ganjiwale
(Dr. R. O. Ganjiwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgun (Meghe), Wardha

- ▶ Dr. Rajendra P. Marathe
- ▶ Dr. Bhushankumar S. Sathe
- ▶ Mr. Jyotiranjana T. Roul

About the Book

This textbook is based on the syllabus prescribed by the Pharmacy Council of India. The salient features of this book are :

- Full coverage of PCI syllabus.
- Easy to understand language.
- Points to Remember & Exercises.
- Clear and Sharp Printing

About the Authors



Dr. Rajendra P. Marathe is currently working as **Principal** at **Government College of Pharmacy, Ratnagiri, Maharashtra**. He holds rich academic experience of around **30 years** in areas of pharmaceutical chemistry, phytopharmacology across various educational settings all over Maharashtra. He has completed his **M. Pharm** from NDMVPS'S College of Pharmacy, Nashik in 1989 and **Ph.D.** from Government College of Pharmacy, Aurangabad in 2010. He is recipient of "**Best Principal Award**" in 1999 from IPER, Pune. He has previously worked as **Chairman**,

Board of Studies, Dr. B. A. M. University, Board of Studies member of Pune University. He has also served as **Vice President, APTI, Maharashtra State**. He has delivered many guest lectures and conducted many seminars as well as workshops all over India. He has written many books for Diploma and Degree pharmacy students.



Dr. Bhushankumar S. Sathe holds rich academic experience of around **16 years** in areas of **Pharmaceutical Chemistry, Pharmaceutical Analysis, and Phytopharmacology**. He has many research publications in various journals of **International and National** repute. He is currently working as **Principal** at **VYWS'S Institute of Diploma in Pharmacy, (Government Aided) Borgaon (Meghe), Wardha**. He is recipient of many awards like "**Best Principal Award**" by SPER [Society for Pharmaceutical Education & Research], "**India's Most Prominent Pharma**

Award-2019" by Prisal [Pharmaceutical Royal International Society], **Pharma Ratan Young Achiever Award-2018 in Academic Category**. He has delivered many guest lectures all over India. He has written many books for Diploma as well as Degree pharmacy students. He is life member of **APTI, SPER**.



Mr. Jyotiranjan T. Roul is currently working as an **Assistant Professor** at Department of Pharmacology, Institute of Pharmaceutical Education and Research, Borgaon (Meghe), Wardha. He is having **13 years** of experience in **teaching** and **research** across various educational settings all over India. He has completed his **B. Pharm** and **M. Pharm** from University Department of Pharmaceutical Sciences, Utkal University, Bhubaneswar, Odisha in the year 2004 and 2006 respectively. He has published many peer review research articles, books. His

areas of research include nanocomposite **drug delivery, preclinical study, toxicological screening**. He is also an editorial board member of two academic journals. He is life member of **SPER [Society for Pharmaceutical Education & Research]**.

OUR HIGHLY RECOMMENDED TEXTBOOKS FOR B. PHARM II SEM.

Author	Author Name
Human Anatomy and Physiology - II	Mrs. Shubhada V. Mangrulkar, Ms. Nitu L. Wankhede Dr. (Mrs.) Shilpa A. Deshpande, Dr. Dinesh R. Chaple
Pharmaceutical Organic Chemistry - I	Dr. Jagdish Baheti, Dr. Parimal Katolkar
Biochemistry	Dr. R. A. Sahu, Dr. A. P. Gangwal, Mrs. R. R. Mishra, Mr. M. P. Sonekar
Pathophysiology	Dr. R. P. Marathe, Dr. B. S. Sathe, Mr. Jyotiranjan T. Roul


Published By :

ABD PUBLISHERS & PRINTERS

Distributed By : **VBD PUBLICATIONS**

Plot No. 236, Near Ram Coolers, Beside
Navi Shukrawari, Mahal, Nagpur-18 Ph




(Dr. R. O. Ganjwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgaon (Meghe), Wardha

About the Book

This textbook is based on the syllabus prescribed by the Pharmacy Council of India. The salient features of this book are:

- Full coverage of PCI syllabus.
- Easy to understand language.
- Points to Remember & Exercises.
- Viva-voce for practical examination.

About the Authors



Dr. (Mrs.) Manisha P. Puranik, is presently working as an **Associate Professor** in Institute of Pharmaceutical Education and Research (IPER), RTM Nagpur University, Boregaon, Wardha, Maharashtra, India. She has more than **25 years** experience in teaching medicinal and organic chemistry at both undergraduate and post-graduate levels. Her research interest includes rational design of small molecular weight ligands as therapeutic inhibitors and pharmaceutical analysis. She has published more than **40 important Research and Review Papers** in reputed **National and International Journals**. She has received **awards for presenting original research works** in Conferences. She is a member of a number of professional and scientific societies such as **IPA, APTI, ISTE, SPER**, etc.



Debarshi Kar Mahapatra, is currently an **Assistant Professor** at the Department of Pharmaceutical Chemistry, Dadasaheb Balpande College of Pharmacy, RTM Nagpur University, Nagpur, India. He obtained his **B. Pharm** and **M. Pharm** from Guru Ghasidas Vishwavidyalaya (Central University) Bilaspur. He has published **several research papers, review articles, imperative case-studies** in various reputed **international journals** and presented his original contributions at several **international platforms**, for which he received several **awards** by a number of **scientific and professional bodies**. Presently, he is serving as **reviewer and editorial board member** for **several journals of international repute**. He is a **member** of a number of **professional and international scientific societies**.

OUR HIGHLY RECOMMENDED TEXTBOOKS FOR B. PHARM VI SEM.

Subjects	Author Name
Medicinal Chemistry - III	Dr. (Mrs.) M. P. Puranik, D.K. Mahapatra
Pharmacology - III	Dr. J.R. Baheti, D.K. Mahapatra, S. S. Borkar, S. B. Wakodkar
Herbal Drug Technology	Dr. V. D. Gulkari, Dr. B. N. Shah, Dr. (Mrs.) S. P. Motghare, Mrs. S. G. Gurunani
Biopharmaceutics & Pharmacokinetics	Dr. (Mrs.) J. G. Avari, Dr. R. H. Kasliwal, Mr. Y. N. Gholse
Pharmaceutical Biotechnology	Dr. (Mrs.) K. Upadhye, Dr. R. H. Kasliwal, Mr. A. R. Thakre
Pharmaceutical Quality Assurance	Dr. A. N. Maliye, Dr. Rajesh A. Sahu, Mrs. R. R. Mishra

Published By :

ABD PUBLISHERS & PRINTERS (P) LTD.

Distributed By : VBD PUBLICATIONS (P) LTD.

Plot No. 236, Near Ram Coolers, Besides Ganesh Temple, Singada Market, Navi Shukrawan, Mahal, Nagpur-18 Ph. : 0712-2722235/36, 7620288004

ISBN : 978-93-87037-27-4



TPS


MEDICINAL CHEMISTRY - III

Sixth Sem. B. Pharm

TPS "Textbook"

Technical Pharmacy Series


Strictly Based On PCI Syllabus



MEDICINAL CHEMISTRY - III



SIXTH SEM. B. PHARM



(Dr. R. O. Ganjiwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Boregaon (Meghe), Wardha

For On-line Purchases, Please Visit


vbdpublications.com OR amazon.in

► Dr. (Mrs.) Manisha P. Puranik

► Debarshi Kar Mahapatra

Nanobiotechnology in Diagnosis, Drug Delivery, and Treatment




(Dr. R. O. Ganjiwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgun (Moghe), Wardha

Nanobiotechnology in Diagnosis, Drug Delivery, and Treatment

Edited by

Mahendra Rai

Nanobiotechnology Laboratory
Department of Biotechnology
Sant Gadge Baba Amravati University
Amravati, Maharashtra, India


Mehdi Razzaghi-Abyaneh

Department of Mycology
Pasteur Institute of Iran
Tehran, Iran

Avinash P. Ingle

Department of Biotechnology
Engineering School of Lorena
University of Sao Paulo
Lorena, Sao Paulo, Brazil




(Dr. R. O. Ganjwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgnour (Moghe), Wardha

WILEY Blackwell

This edition first published 2021
© 2021 John Wiley & Sons Ltd

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at <http://www.wiley.com/go/permissions>.

The right of Mahendra Rai, Mehdi Razzaghi-Abyaneh, and Avinash P. Ingle to be identified as the authors of the editorial material in this work has been asserted in accordance with law.

Registered Offices

John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA
John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

Editorial Office

The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com.

Wiley also publishes its books in a variety of electronic formats and by print-on-demand. Some content that appears in standard print versions of this book may not be available in other formats.

Limit of Liability/Disclaimer of Warranty


While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

Library of Congress Cataloging-in-Publication Data applied for
ISBN Paperback: 9781119671770

Cover Design: Wiley
Cover Image: © LAGUNA DESIGN/Getty Images

Set in 9.5/12.5pt STIXTwoText by SPi Global, Pondicherry, India

10 9 8 7 6 5 4 3 2 1



Contents

List of Contributors vii

Preface xi

- 1 **Nanotechnology: A New Era in the Revolution of Drug Delivery, Diagnosis, and Treatment of Diseases** 1
Avinash P. Ingle, Patrycja Golińska, Alka Yadav, Mehdi Razzaghi-Abyaneh, Mrunali Patel, Rashmin Patel, Yulia Plekhanova, Anatoly Reshetilov, and Mahendra Rai
- 2 **Selenium Nanocomposites in Diagnosis, Drug Delivery, and Treatment** 25
Irina A. Shurygina and Michael G. Shurygin
- 3 **Emerging Applications of Nanomaterials in the Diagnosis and Treatment of Gastrointestinal Disorders** 47
Patrycja Golińska and Magdalena Wypij
- 4 **Nanotheranostics: Novel Materials for Targeted Therapy and Diagnosis** 63
Sougata Ghosh and Rohini Kitture
- 5 **Aptamer-Incorporated Nanoparticle Systems for Drug Delivery** 95
Fahimeh Charbgo, Seyed Mohammad Taghdisi, Rezvan Yazdian-Robati, Khalil Abnous, Mohammad Ramezani, and Mona Alibolandi
- 6 **Application of Nanotechnology in Transdermal Drug Delivery** 113
Dilesh Jagdish Singhavi and Shagufta Khan
- 7 **Superparamagnetic Iron Oxide Nanoparticle-Based Drug Delivery in Cancer Therapeutics** 129
Dipak Maity, Atul Sudame, and Ganeshlenin Kandasamy
- 8 **Virus-Like Nanoparticle-Mediated Delivery of Cancer Therapeutics** 153
Yasser Shahzad, Abid Mehmood Yousaf, Talib Hussain, and Syed A.A. Rizvi
- 9 **Magnetic Nanoparticles: An Emergent Platform for Future Cancer Theranostics** 171
Parinaz Nezhad-Mokhtari, Fatemeh Salahpour-Anarjan, Armin Rezanezhad, and Abolfazl Akbarzadeh



(Dr. R. O. Ganjivale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgoo (Moghe), Wardha

- 10 Chitosan Nanoparticles: A Novel Antimicrobial Agent** 197
Divya Koilparambil, Sherin Varghese, and Jisha Manakulam Shaikmoideen
- 11 Sulfur Nanoparticles: Biosynthesis, Antibacterial Applications, and Their Mechanism of Action** 217
Priti Paralikar and Mahendra Rai
- 12 Role of Nanotechnology in the Management of Indoor Fungi** 229
Erasmó Gámez-Espinosa, Leyanet Barberia-Roque, and Natalia Bellotti
- 13 Nanotechnology for Antifungal Therapy** 259
Jaqueline Teixeira da Silva and Andre Correa Amaral
- 14 Chitosan Conjugate of Biogenic Silver Nanoparticles: A Promising Drug Formulation with Antimicrobial and Anticancer Activities** 273
Smitha Vijayan and Jisha Manakulam Shaikmoideen
- 15 Leishmaniasis: Where Infection and Nanoparticles Meet** 295
Mohammad Imani and Azam Dehghan
- 16 Theranostics and Vaccines: Current Status and Future Expectations** 359
Thais Francine Ribeiro Alves, Fernando Batain, Cecília Torqueti de Barros, Kessie Marie Moura Crescencio, Venâncio Alves do Amaral, Mariana Silveira de Alcântara Chaud, Décio Luís Portella, and Marco Vinícius Chaud
- 17 Toxicological Concerns of Nanomaterials Used in Biomedical Applications** 375
Avinash P. Ingle, Indarchand Gupta, and Mahendra Rai
- Index** 399



(Dr. R. O. Ganjivale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgnour (Moghe), Wardha

Nanobiotechnology in Diagnosis, Drug Delivery, and Treatment

Chapter 6

Application of Nanotechnology in Transdermal Drug Delivery

Dilesh Jagdish Singhavi, Shagufta Khan,

Book Editor(s): Mahendra Rai, Mehdi Razzaghi-Abyaneh, Avinash P. Ingle,


First published: 17 November 2020

<https://doi.org/10.1002/9781119671732.ch6>

Summary

The stratum corneum presents a tough barrier for delivery of drugs through the skin. There is interest in the use of nanoparticles as drug delivery carrier systems because these systems are potentially superior to other carrier systems in terms of controlled release, targeting, and stability. In recent years, a great deal of attention has been given to polymeric nanoparticles for delivering drugs to the skin. A detailed explanation of the interaction of the skin and nanoparticles will enhance the reader's understanding of new concepts and the use of drug delivery carriers in transdermal delivery. The mechanism of penetration/permeation of drug from different nanocarriers plays an important role not only in targeting drugs within skin, but also in development strategies of nanocarriers. This chapter provides an overview of the design of nanocarrier-based drug delivery systems for transdermal drug delivery. The potential of nanotechnology in transdermal drug delivery is highlighted. The influence of the physicochemical properties of nanocarriers on transdermal drug delivery has also been given attention. Finally, the chapter concludes with future drug delivery.





(Dr. R. O. Ganjiwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgun (Moghe), Wardha

I drug

As Per PCI Regulations
Final Year B. Pharm. • Semester-VIII

SOCIAL AND PREVENTIVE PHARMACY

SOURABH KOSEY
SANJAY NAGDEV
ASHISH BUDHRANI



Signature
(Dr. R. O. Ganjwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgun (Stephe), Wardha

 **NIRALI**
PRAKASHAN
ADVANCEMENT OF KNOWLEDGE

First Edition : January 2021

AUTHORS

The text of this publication, or any part thereof, should not be reproduced or transmitted in any form or stored in any computer storage system or device for distribution including photocopy, recording, taping or information retrieval system or reproduced on any disc, tape, perforated media or other information storage device etc., without the written permission of Author with whom the rights are reserved. Breach of this condition is liable for legal action.

Every effort has been made to avoid errors or omissions in this publication. In spite of this, errors may have crept in. Any mistake, error or discrepancy so noted and shall be brought to our notice shall be taken care of in the next edition. It is notified that neither the publisher nor the author or seller shall be responsible for any damage or loss of action to any one, of any kind, in any manner, therefrom.

Published By : **NIRALI PRAKASHAN** Polyplate

Abhyudaya Pragati, 1312, Shivaji Nagar,
Off J.M. Road, PUNE - 411005
Tel - (020) 25512336/37/39, Fax - (020) 25511379
Email : niralipune@pragationline.com

Printed By : **YOGIRAJ PRINTERS AND BINDERS**
Works: Sr. No. 10\1, Ghule Industrial Estate,
Nanded Village Road,
TAL-HAVELI, DIT-PUNE 411041.
Mobile - 9850046517, 9404225254

DISTRIBUTION CENTRES**PUNE**

Nirali Prakashan : 119, Budhwar Peth, Jogeshwari Mandir Lane, Pune 411002, Maharashtra
(For orders within Pune) Tel : (020) 2445 2044, Mobile : 9657703145
Email : bookorder@pragationline.com, niralilocal@pragationline.com

Nirali Prakashan : S. No. 28/27, Dhyari, Near Pari Company, Pune 411041
(For orders outside Pune) Tel : (020) 24690204 Fax : (020) 24690316; Mobile : 9657703143
Email : dhyari@pragationline.com, bookorder@pragationline.com

MUMBAI

Nirali Prakashan : 385, S.V.P. Road, Rasdhara Co-op. Hsg. Society Ltd.,
Girgaum, Mumbai 400004, Maharashtra; Mobile : 9320129587
Tel : (022) 2385 6339 / 2386 9976, Fax : (022) 2386 9976
Email : niralimumbai@pragationline.com

DISTRIBUTION BRANCHES**JALGAON**

Nirali Prakashan : 34, V. V. Golani Market, Navi Peth, Jalgaon 425001,
Maharashtra, Tel : (0257) 222 0395, Mob : 94234 91860

KOLHAPUR

Nirali Prakashan : New Mahadvar Road, Kedar Plaza, 1st Floor Opp. IDBI Bank
Kolhapur 416 012, Maharashtra. Mob : 9850046155

NAGPUR

Nirali Prakashan : Above Maratha Mandir, Shop No. 3, First Floor,
Rani Jhanshi Square, Sitabuldi, Nagpur 440012, Maharashtra
Tel : (0712) 254 7129

DELHI

Nirali Prakashan : Room. No. 2 Ground Floor, 4575/15 Omkar Tower,
Agarwal Road, Darya Ganj, New Delhi - 110002.
Mob : 9555778814 / 9818561840 - Email : niralidelhi@pragationline.com

BENGALURU

Nirali Prakashan : Maitri Ground Floor, Jaya Apartments, No. 99, 6th Cross, 6th Main,
Malleswaram, Bengaluru 560003, Karnataka; Mob : 9449043034
Email: niralibangalore@pragationline.com

Note: Every possible effort has
or mistake so noted, and shall
the author or book seller shall
must cross check all the facts:



Dr. R. O. Ganjiwale
(Dr. R. O. Ganjiwale)

Principal


PRINCIPAL

Institute of Pharmaceutical Education & Research
Borgun (Steghe), Wardha

Any type of error
the publisher, nor
from. The reader

1. Concept of Health and Disease	1.1 - 1.6
1.1 Introduction	1.1
1.1.1 Definition	1.1
1.1.2 Features of Good Health	1.1
1.2 Essential Requirements for Maintaining a Good Health	1.1
1.2.1 Healthy and Maintained Diet	1.2
1.2.2 Good Habits for Good Health	1.2
1.2.3 Exercise and Rest for Good Health	1.2
1.3 Factors Affecting Health	1.2
1.4 Evaluation of Public Health	1.3
1.4.1 Reasons behind Developing Framework	1.3
1.4.2 Types of Evaluations	1.3
1.5 Prevention and Control of Disease	1.3
1.5.1 Some Important Points for Control and Prevention of Disease	1.4
1.5.2 Levels of Prevention	1.4
1.6 Social Causes of Diseases	1.4
1.7 Social Problems of the Sick	1.5
• Review Questions	1.6
2. Social and Health Education	2.1 - 2.12
2.1 Social Education	2.1
2.2 Health Education	2.1
2.2.1 Principles of Health Education	2.2
2.2.2 Definitions	2.2
2.2.3 Importance of Health Education	2.2
2.3 Food In Relation To Nutrition and Health	2.2
2.3.1 Healthy Diet and Nutrition	2.3
2.3.2 Healthy Diet and Mental Health	2.3
2.3.3 Healthy Diet and Cancer	2.3
2.3.4 Healthy Diet and Skeletal Disease	2.4
2.3.5 Healthy Diet and Chronic Diseases	2.4
2.3.6 Healthy Diet and Dental Diseases	2.4
2.4 Balanced Diet	2.4
2.4.1 Importance of a Balanced Diet	2.5
2.4.2 Balanced Diet	2.6
2.4.3 Organization of Balanced Diet	2.7
2.5 Nutritional Deficiency	2.7
2.5.1 Macronutrients	2.8
2.5.2 Micronutrients	2.9
2.6 Vitamin Deficiencies	2.9
2.7 Malnutrition and Its Prevention	2.10
2.7.1 Types of Malnutrition	2.10
2.7.2 Causes of Malnutrition	2.11
2.7.3 Symptoms of Malnutrition	2.11





 (Dr. R. O. Ganjivale)
 Principal
 PRINCIPAL
 Institute of Pharmaceutical Education & Research
 Borgou (Nighe), Wardha

2.7.4	Prevention	2.11
•	Review Questions	2.11
3.	Sociology and Health	3.1 - 3.4
3.1	Sociology	3.1
3.2	Types of Sociology	3.1
3.3	Socio-Cultural Factors Related To Health and Disease	3.1
3.4	Impact of Urbanization on Health and Disease	3.2
3.4.1	Urbanization	3.2
3.4.2	Impact of Urbanization on Health and Disease	3.2
3.4.3	Health Hazards due to Poor Water Supply and Sanitation	3.3
3.5	Poverty and Health	3.3
3.5.1	Effects of Poverty on Health	3.3
3.5.2	Important Steps to Decrease Poverty	3.3
•	Review Questions	3.4
4.	Hygiene and Health	4.1 - 4.4
4.1	Introduction	4.1
4.2	Types of Health	4.1
4.3	Types of Hygiene	4.2
4.4	Personal Hygiene and Health Care	4.2
4.5	Principles of Personal Hygiene	4.2
4.5.1	Objectives	4.3
4.5.2	Personal Hygiene	4.3
4.5.3	Benefits of Personal Hygiene	4.3
4.6	Some Common Habits That Should Be Avoided	4.3
•	Review Questions	4.4

Unit - II

5.	Preventive Medicine	5.1 - 5.44
5.1	Types of Disease Prevention	5.1
5.2	Cholera	5.2
5.2.1	Definition	5.2
5.2.2	Epidemiology	5.2
5.2.4	Host Factor	5.2
5.2.5	Environmental Factors	5.3
5.2.6	Incubation Period	5.3
5.2.7	Mode of Transmission	5.3
5.2.8	Symptoms of Cholera Disease	5.3
5.2.9	Laboratory Diagnosis	5.3
5.2.10	Prevention and Control of Cholera	5.4
5.3	Severe Acute Respiratory Syndrome (SARS)	5.6
5.3.1	Definition	5.6
5.3.2	SARS Corona Virus	5.6
5.3.3	Epidemiology	5.6
5.3.4	Agents/Factors	5.6
5.3.5	Host Factor	5.6
5.3.6	Environmental Factors	5.6
5.3.7	Incubation Period	5.7




 (Dr. R. O. Ganjivale)
 Principal
 INSTITUTE OF PHARMACEUTICAL EDUCATION & RESEARCH
 Warananagar (M.S.), Warananagar

5.3.8	Mode of Transmission	5.7
5.3.9	Symptoms of SARS	5.7
5.3.10	Laboratory Diagnosis	5.7
5.3.11	Prevention and Control of SARS	5.9
5.4	Influenza	5.9
5.4.1	Definition	5.9
5.4.2	Types	5.10
5.4.3	Epidemiology	5.10
5.4.4	Agents/Factors	5.10
5.4.5	Host Factor	5.10
5.4.6	Environmental Factors	5.10
5.4.7	Mode of Transmission	5.11
5.4.8	Symptoms of Influenza	5.11
5.4.9	Laboratory Diagnosis	5.11
5.4.10	Prevention and Control of Influenza	5.12
5.5	Acute Respiratory Infections	5.12
5.5.1	Epidemiology	5.13
5.5.2	Agents/Factors	5.13
5.5.3	Host Factor	5.13
5.5.4	Environmental Factors	5.13
5.5.5	Incubation Period	5.13
5.5.6	Modes of Transmission	5.13
5.5.7	Symptoms of ARI	5.14
5.5.8	Prevention and Control of Acute Respiratory Infections	5.14
5.6	Chikungunya	5.15
5.6.1	Epidemiology	5.15
5.6.2	Agent/Factor	5.15
5.6.3	Host Factors	5.15
5.6.4	Environmental Factors	5.15
5.6.5	Incubation Period	5.16
5.6.6	Mode of Transmission	5.16
5.6.7	Symptoms	5.16
5.6.8	Laboratory Diagnosis	5.16
5.6.9	Prevention and Control of Chikungunya	5.17
5.7	Lymphatic Filariasis	5.18
5.7.1	Epidemiology	5.18
5.7.2	Agents/Factor	5.18
5.7.3	Host Factor	5.19
5.7.4	Environmental Factors	5.19
5.7.5	Incubation Period	5.19
5.7.6	Mode of Transmission	5.19
5.7.7	Symptoms	5.19
5.7.8	Laboratory Diagnosis	5.19
5.7.9	Prevention and Control	5.20
5.8	Pneumonia	5.20
5.8.1	Epidemiology	5.21
5.8.2	Agent/Factor	5.21
5.8.3	Host Factor	5.21

Unit - II




(Dr. R. O. Ganjivale)
Principal

Institute of Pharmaceutical Education & Research
Bargarh (Odisha), Warangal

5.8.4	Environmental Factors	5.21
5.8.5	Incubation Period	5.21
5.8.6	Mode of transmission	5.21
5.8.7	Symptoms	5.21
5.8.8	Laboratory Diagnosis	5.21
5.8.9	Prevention and Control	5.21
5.9	Ebola Virus	5.22
5.9.1	Epidemiology	5.22
5.9.2	Agent/Factor	5.22
5.9.3	Host Factor	5.23
5.9.4	Environment Factors	5.23
5.9.5	Incubation Period	5.23
5.9.6	Mode of Transmission	5.23
5.9.7	Symptoms of Ebola Virus	5.23
5.9.8	Laboratory Diagnosis	5.23
5.9.9	Prevention and Control	5.24
5.10	Dengue	5.24
5.10.1	Epidemiology	5.24
5.10.2	Agent/Factor	5.25
5.10.3	Host Factor	5.25
5.10.4	Environmental Factor	5.25
5.10.5	Incubation Period	5.25
5.10.6	Mode of Transmission	5.25
5.10.7	Symptoms	5.25
5.10.8	Laboratory Diagnosis	5.26
5.10.9	Prevention and Control	5.26
5.11	Malaria	5.27
5.11.1	Epidemiology	5.27
5.11.2	Agents/Factors	5.28
5.11.3	Host Factors	5.28
5.11.4	Environmental Factors	5.28
5.11.5	Incubation Period	5.28
5.11.6	Mode of Transmission	5.29
5.11.7	Symptoms	5.29
5.11.8	Laboratory Diagnosis	5.29
5.11.9	Prevention and Control of Malaria	5.29
5.12	Hypertension	5.32
5.12.1	Agents	5.32
5.12.2	Host Factors	5.32
5.12.3	Environmental Factors	5.33
5.12.4	Prevention and Control	5.33
5.13	Cancer	5.34
5.13.1	Causes of Cancer	5.34
5.13.2	Prevention and Control	5.35
5.14	Diabetes Mellitus	5.35
5.14.1	Types of Diabetes Mellitus	5.36
5.14.2	Agent	5.36
5.14.3	Host Factor	5.36




 (Dr. R. O. Ganjivale)
 Principal
 PRINTEX
 Institute of Pharmaceutical Education & Research
 Borgun (Stogie), Warananagar

- 5.14.4 Environmental Factors
- 5.14.5 Prevention and Control of Diabetes
- 5.15 Drug Addiction- Drug Substance Abuse
 - 5.15.1 Introduction
 - 5.15.2 Reasons for Drug Addiction
 - 5.15.3 Narcotic Analgesics (Opiates)
 - 5.15.4 CNS Depressants
 - 5.15.5 Barbiturate
- Review Questions

Unit - III

6. National Health Programme

- 6.1 Introduction
- 6.2 Health Care Services
- 6.3 Health Care Systems
- 6.4 Objectives of the Programme
- 6.5 HIV and Aids Control Programme
 - 6.5.1 National Control Programme for HIV/AIDS and its Functioning
 - 6.5.2 Objectives of HIV and AIDS Control Programme
 - 6.5.3 National AIDS Control Programme and its Functioning
- 6.6 Tuberculosis
 - 6.6.1 National Health Programme for Tuberculosis and it's Functioning
 - 6.6.2 National Strategic Plan for 2012-2017
 - 6.6.3 National Strategic Plan for 2017-2025 for TB Elimination in India
 - 6.6.4 Improving TB Surveillance by Transitioning to Case Based, Web Based Recording and Reporting (NIKSHAY)
 - 6.6.5 TB Co-Morbidities
 - 6.6.6 Objectives of Tuberculosis Control Programme
 - 6.6.7 Outcomes of Programmes
- 6.7 National Leprosy Control Programme
 - 6.7.1 National Control Programme for Leprosy and its Functioning
 - 6.7.2 National Leprosy Programmes
 - 6.7.3 Objectives of National Leprosy Programme
 - 6.7.4 Outcomes of Programmes
- 6.8 National Mental Health Programme
 - 6.8.1 National Mental Health Programme and its Functioning
 - 6.8.2 Aim
 - 6.8.3 The Objectives of National Mental Health Programme
 - 6.8.4 Outcomes of Programme
- 6.9 National Programme For Control Of Blindness
 - 6.9.1 National Programme for Control of Blindness and its Functioning
 - 6.9.2 Activities Under Programme for Control of Blindness
 - 6.9.3 Functioning
 - 6.9.4 Strategies
 - 6.9.5 Goals and Objective of
 - 6.9.6 Outcomes of Programm
- 6.10 Pulse Polio Programme
 - 6.10.1 National Programme of



(Signature)
(Dr. R. O. Ganjivale)

Principal

PRINCIPAL

Institute of Pharmaceutical Education & Research
Borgun (Moghe), Wardha

5.36
5.36
5.38
5.38
5.39
5.39
5.40
5.41
5.42

6.1 - 6.24

6.1
6.1
6.2
6.2
6.2
6.2
6.3
6.4
6.6
6.6
6.7
6.7
6.7
6.8
6.8
6.8
6.9
6.9
6.9
6.10
6.10
6.11
6.11
6.11
6.11
6.11
6.12
6.12
6.12
6.12
6.13
6.13
6.14
6.14
6.14
6.14

6.10.2	Principle for Polio Elimination	6.14
6.10.3	National Programme of Pulse Polio and its Functioning	6.14
6.10.4	Functioning	6.15
6.10.5	Strategies for Polio Elimination	6.15
6.10.6	Objectives	6.15
6.10.7	Outcomes of the Programme	6.16
6.11	Universal Immunization Programme	6.16
6.11.1	Universal Immunization Programme and its Functioning	6.16
6.11.2	Schedule of Universal Immunization Programme	6.17
6.11.3	Strategies of Universal Immunization Programme	6.18
6.11.4	Objectives	6.18
6.11.5	Outcomes of the Programme	6.19
6.12	Integrated Disease Surveillance Programme	6.19
6.12.1	Elements of Surveillance Activity	6.19
6.12.2	Types of Surveillance in Integrated Disease Surveillance Programme (IDSP)	6.20
6.12.3	Functions and Strategies of IDSP	6.20
6.12.4	Objectives	6.20
6.12.5	Outcomes of the Programme	6.21
6.13	National Programme For Prevention And Control Of Deafness	6.21
6.13.1	Components of the Programme	6.22
6.13.2	Functions	6.22
6.13.3	Objectives	6.22
6.13.4	Long Term Objective	6.23
6.13.5	Outcomes	6.23
•	Review Questions	6.23

Unit - IV

7. National Health Intervention Programme for Mother and Child 7.1 - 7.16

7.1	Introduction	7.1
7.2	Development of Mother and Child Health Programme	7.1
7.2.1	Objectives of Mother and Child Health Programmes	7.2
7.2.2	Aims of Mother and Child Health Services	7.2
7.2.3	Components of Reproductive and Child Health	7.3
7.2.4	Importance of Maternal and Child Health Services	7.3
7.2.5	Mother and Child Health Services (MCH)	7.3
7.3	National Family Welfare Programme	7.5
7.3.1	Concept of Family Welfare Programme	7.5
7.3.2	Aims and Objectives	7.6
7.3.3	Goals	7.6
7.3.4	Role of Pharmacist	7.6
7.4	National Tobacco Control Programme (NTCP)	7.6
7.4.1	Objectives	7.7
7.4.2	List of Diseases Caused by Tobacco	7.8
7.5	National Malaria Prevention Prog	7.8
7.5.1	Objective	7.8
7.5.2	Strategies Under NMCP	7.8
7.5.3	Malaria Control Activities	7.9



PART I: BASICS CONCEPTS AND GLOBAL PROGRESS IN NUTRACEUTICAL SCIENCES

1. Recent Facts and Global Perspectives of Nutraceuticals in Medicine

Manisha Puranik, Jyotiranjana Roul, and Pramod Yeole

2. Recent Techniques in Isolation of Nutraceuticals from Plants

Sumit Arora, Shobha Ubgade, and Alok Ubgade

PART II: ADVANCES IN NANOPARTICLES-BASED NUTRACEUTICAL DELIVERY

3. Solid Lipid Nanoparticles (SLNs): An Emerging Platform for Nutraceutical Delivery

Vishal C. Gurumukhi, Sanjaykumar B. Bari, and Kaushalendra Chaturvedi

4. Fabrication Methods of Therapeutic Nanoparticles: Potential Opportunities and Challenges in Drug Delivery and Nutraceutical Delivery

Swapnil G. Patil, Surendra G. Gattani, Kiran Patil, Shashikant Bagade, and Debarshi Kar Mahapatra

5. Polymeric Nanoparticles-Based Nutraceutical Delivery System

Mahesh P. More, Prashant K. Deshmukh, Prajakta Joshi, and Prasad A. Pofali

PART III: ADVANCES IN VESICULAR DELIVERY SYSTEMS FOR NUTRACEUTICAL APPLICATIONS

6. Phytosomes and Phytosomal Nanoparticles: A Promising Drug Delivery System for Flavonoids and Nutraceuticals

Darshan R. Telange, Shirish P. Jain, Anil M. Pethe, and Vivek S. Dave

7. Liposomal Delivery System for the Effective Delivery of Nutraceuticals and Functional Foods

Pranesh Kumar, Debarshi Kar Mahapatra, Dileep Kumar, Mohamad Taleuzzmann, Sachin Borikar, Vishal S. Gulecha, Amar G. Zalte, Kanhaiya M. Dadure, Manisha Puranik, Manik Das, and Tomy Muringayil Joseph

PART IV: BIPHASIC SYSTEMS FOR DELIVERING NUTRACEUTICAL PRODUCTS

8. Self-Emulsifying Drug Delivery System for Potential Nutraceuticals: Solidification Techniques and Quality by Design (QBD)

Shailesh S. Chalikwar, Pankaj V. Dangre, Poorva P. Dusad, and Sanjay J. Surana

9. Microemulsions for Improvement in Bioavailability of Potential Nutraceuticals

Vaishali Kilor, Nidhi Sapkal, Shobha Ubgade, and Abhay Itadwar

PART V: ADVANCED INNOVATIVE NUTRACEUTICAL DELIVERY SYSTEMS

10. Challenges in Oral Delivery of Nutraceuticals: From Formulation Scale-Up to Clinical Assessment

Kaushalendra Chaturvedi, Harsh Shah, and Bhavin Gajera

11. Solid Dispersion Techniques for Improvement of Dissolution and Bioavailability of Nutraceuticals

Abhijeet D. Kulkarni, Unnati M. Patel, Pallavi S. Kandalkar, Ankita A. Gorhe, Anjali S. Sabale, Asmita K. Kedar, Snehal S. Jagtap, and Vaibhav A. Mahale

12. Potential Applications of Polyelectrolyte Complexes in Pharmaceutical and Nutraceutical Delivery

Chandrakantsing V. Pardeshi, Debarshi Kar Mahapatra, Veena S. Belgamwar, and Sanjay J. Surana

13. Micelles: An Insight for Nutraceuticals and Regulatory Status

Pankaj Padmakar Nerkar

14. Insights into the Latest Taste-Masking Techniques for Nutraceutical Products and Functional Foods

Parag A. Kulkarni, Amit B. Page, and Debarshi Kar Mahapatra



(Dr. R. O. Ganjiwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgun (Ateghe), Wardha

NUTRACEUTICALS IN MEDICINE

Manisha Puranik*, Jyotiranjana Roul, Pramod Yeole

Institute of Pharmaceutical Education and Research, Borgaon (Meghe), Wardha, Maharashtra,
India

*E-mail: manisha68_12@yahoo.com


ABSTRACT

The book chapter comprehensively describes the fundamentals of nutraceuticals, translated concepts, plausible benefits, developed new products (vitamin, minerals, herbal, polyphenols, dietary fiber, etc.), paradigms, challenges, global economy, worldwide demands, global scenario, and regulatory aspects (USA, Europe, Japan, and India).

KEYWORDS

- Nutraceutical
- Functional food
- Products
- Scenario
- Regulatory
- Guidelines
- Challenges
- Demands




(Dr. R. O. Ganjivale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgaon (Meghe), Wardha

Liposomal Delivery System for the Effective Delivery of Nutraceuticals and Functional Foods

Pranesh Kumar ¹, Debarshi Kar Mahapatra ^{2*}, Dileep Kumar ³, Mohamad Taleuzzmann ⁴, Sachin Borikar ⁵, Vishal S. Gulecha ⁶, Amar G. Zalte ⁶, Kanhaiya M. Dadure ⁷, Manisha Puranik ⁸, Manik Das ⁹, Tomy Muringayil Joseph ¹⁰

*Corresponding Author

mahapatradebarshi@gmail.com

¹Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University (A Central University), Lucknow, Uttar Pradesh, India

²Department of Pharmaceutical Chemistry, Dadasaheb Balpande College of Pharmacy, Nagpur, Maharashtra, India

³Department of Pharmaceutical Chemistry, Poona College of Pharmacy, Bharati Vidyapeeth (A Deemed to be University), Pune, Maharashtra, India

⁴Faculty of Pharmacy, Maulana Azad University, Jodhpur, Rajasthan, India

⁵Department of Pharmacology, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Dhule, Maharashtra, India

⁶School of Pharmaceutical Sciences, Sandip University, Nashik, Maharashtra, India

⁷Department of Chemistry, J. B. College of Science, Wardha 442001, Maharashtra, India


⁸Institute of Pharmaceutical Education and Research, Borgaon (Meghe), Wardha, Maharashtra, India

⁹Department of Pharmaceutical Chemistry, Gokaraju Rangaraju College of Pharmacy, Hyderabad, Telangana, India

¹⁰Chemical Faculty, Polymers Technology Department, Gdansk University of Technology, Gdansk 80233, Poland

Short Title: Liposomal Nutraceuticals Delivery System





(Dr. R. O. Ganjivale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgaon (Meghe), Wardha

Concise Course in
PHARMACOLOGY-I

*Strictly as per Syllabus of Pharmacy Council of India,
New Delhi for B. Pharm Semester IV,
Pharm. D, Medicine and Allied Health Sciences*

Dr. Amit Nerkar
Bhushan Varpe
Vaishali Shende ✓
Dattaraya Kature




(Dr. R. O. Ganjivale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgaon (Meghe), Wardha

Pee Vee (Regd.)

An Imprint of

S. VIKAS AND COMPANY (MEDICAL PUBLISHERS)

ADMIN : ND-106, BIKRAMPURA, JALANDHAR CITY-144 008 (PUNJAB), INDIA

SALES : ND-227, TANDA ROAD, JALANDHAR CITY-144 008 (PUNJAB), INDIA

PRODUCTION : ND-226, TANDA ROAD, JALANDHAR CITY-144 008 (PUNJAB), INDIA

PHONES : 094786-64645, 0181-5014275, 0181-3811125

CUSTOMER CARE : For any queries, please contact - 094786-14148

EMAIL : pv_books@yahoo.com

Online Shop : www.pvbooks.in

Also Buy at www.amazon.in 

© Copyrights Reserved

All rights reserved. No part of this publication may be reproduced or used in any form or by any means-photographic, electronic or mechanical including photocopying, recording, taping or information storage and retrieval systems-without the written permission of the publishers

ISBN 97815-43345-27-8

TradeMark No. 1350444

Edition 2021

PRICE : ₹ 375/-

Illustrators : Aakriti Jain

Printed and bound in India

by Choice Books and Printers Pvt. Ltd.

Exclusively marketed and distributed by PV books

For sale only in India, Nepal, Bangladesh, Sri Lanka and U.A.E.

The publishers make no representation implied with regard to the accuracy contained in this book and cannot accept responsibility for any errors or omissions.




(Dr. R. O. Ganjiwale)

Principal

PRINCIPAL

Institute of Pharmaceutical Education & Research
Borgun (Moghe), Wardha

CONTENTS

Chapter 1 General Pharmacology-I 1-96

1.1 Introduction to pharmacology 1, 1.1.1 Basic pharmacology 1, 1.1.2 Historical landmarks 3, 1.1.3 Scope of pharmacology 7, 1.1.4 Nature of drugs 11, 1.1.5 Sources of drugs 13, 1.1.6 Agonists and antagonists 15, 1.1.7 Spare receptors 20, 1.1.8 Addiction 21, 1.1.9 Tolerance 22, 1.1.10 Dependence 23, 1.1.11 Tachyphylaxis 24, 1.1.12 Idiosyncrasy 24, 1.1.13 Allergy 25, 1.2 Pharmacokinetics 28, 1.2.1 Absorption 29, 1.2.2 Membrane transport 30, 1.2.3 Distribution 34, 1.2.4 Metabolism 35, 1.2.5 Excretion 37, 1.2.7 Enzyme induction and inhibition 40, 1.2.8 Kinetics of drug elimination 44

Chapter 2 Pharmacology-II 49-96

2.1 Introduction 49, 2.1.1 Pharmacokinetics 49, 2.1.2 Pharmacodynamics 49, 2.1.3 History 59, 2.1.4 Theories for drug-receptor interactions 60, 2.1.5 Types of receptors 65, 2.1.6 Regulation of receptors 71, 2.1.7 Signal transduction 73, 2.1.8 Dynamic nature of receptors 78, 2.1.9 Drug-receptor interaction 79, 2.1.10 Dose response relationship 82, 2.1.11 Therapeutic efficacy 85, 2.1.12 Combined effects of drug 86, 2.1.13 Factors affecting adverse drug reactions 87, 2.2 Adverse drug reactions 88, 2.2.1 Pharmacovigilance 90, 2.3 Drug interactions 90, 2.3.1 Drug-drug interactions 90, 2.4 Drug discovery and clinical studies 92

Chapter 3 Drugs Acting on Peripheral Nervous System 97-201

3.1 Drugs Acting on Peripheral Nervous System 97, 3.1.1 Organization and function of autonomic nervous system 97, 3.1.2 Neurohumoral transmission 101, 3.1.3 Neurotransmitters 104, 3.2 Cholinergic and anticholinergics 107, 3.2.1 Introduction 107, 3.2.2 Cholinergic receptors 108, 3.2.3 Actions of acetylcholine 108, 3.2.4 Muscarinic receptors 110, 3.2.5 Nicotinic receptors 111, 3.2.6 Biosynthesis, storage, release, and metabolism of acetylcholine 115, 3.2.7 Release 116, 3.2.8 Metabolism 117, 3.2.9 classification of drugs acting on cholinergic system 117, 3.2.10 Specific muscarinic cholinergic agonists 118, 3.2.11 Acetylcholinesterase (ache) inhibitors 121, 3.2.12 Acetylcholinesterase inhibitors for the treatment of alzheimer's disease 124, 3.2.13 Irreversible inhibitors of ache 126, 3.2.14 Antidotes for irreversible acheis 127, 3.2.15 Insecticidal achei's and their antidotes 128, 3.2.16 Acetylcholine antagonists acting agents 140, 3.2.18 Ganglionic stimulants 144, acting agents 149, 3.3 Adrenergic agonists and glaucoma 189, 3.5 Glaucoma 192



(Dr. R. O. Ganjwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgun (Meghe), Wardha

Chapter 4: Pharmacology of Drugs Acting on Central Nervous System-I 202-280

4.1 Neurohumoral transmission **202**, 4.1.1 CNS neurotransmitters **202**, 4.2 General anesthetics and pre-anesthetics **207**, 4.3 Sedative and hypnotics **220**, Centrally acting skeletal muscle relaxants **245**, 4.4 Antiepileptic drugs **255**, 4.4.1 Classification of epilepsies **255**, 4.4.2 Classification of seizures **257**, 4.5 Alcohol and disulfiram **273**

Chapter 5: Pharmacology of Drugs Acting on Central Nervous System-II 281-373

5.1 Pharmacology of drugs acting on central nervous system **281**, 5.1.1 Antipsychotic agents **281**, 5.1.2 Antidepressant agents **300**, Classification of antidepressants **300**, 5.1.3 Anti-anxiety agents **312**, 5.1.4 Antimanics drugs **320**, 5.1.5 Hallucinogens **323**, Types of hallucinogens **325**, 5.2 Drugs used in parkinsonism and alzheimer's disease **331**, 5.2.1 Classification of drugs used in parkinsonism **331**, 5.2.2 Drugs used in alzheimer's disease **336**, 5.3 CNS stimulants and nootropics **342**, 5.3.1 CNS stimulants **342**, 5.3.2 Nootropics **348**, 5.4 Opioid analgesics and antagonist **350**, 5.4.1 Opiodal analgesics (agonists) and opiodal agents classification **352**, 5.4.2 Opiodal antagonists **360**, 5.5 Drug addiction, abuse, tolerance and dependence **365**, 5.5.1 Drug addiction **365**, 5.5.2 Drug abuse **367**, 5.5.3 Tolerance **370**, 5.5.4 Dependence **371**

Index

(i)-(ii)



(Dr. R. O. Ganjiwale)
Principal
PRINCIPAS
Institute of Pharmaceutical Education & Research
Borgou (Moghe), Wardha



A Text Book of

Quality Control and Quality Assurance

*Strictly As Per Syllabus Prescribed for M. Pharmacy
(Pharmaceutical Quality Assurance),
Semester-I by Pharmacy Council of India, New Delhi*

Deepanti Gajjar
Ashish Budhrani
Dr. Md. Raqeeb Md. Usman
Dr. Dilpreet Singh



(Signature)
(Dr. R. O. Ganjivale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgnur (Moghe), Wardha

Pee Vee (Regd.)

An Imprint of

S. VIKAS AND COMPANY (MEDICAL PUBLISHERS)

ADMIN : ND-106, BIKRAMPURA, JALANDHAR CITY-144 008 (PUNJAB), INDIA

SALES : ND-227, TANDA ROAD, JALANDHAR CITY-144 008 (PUNJAB), INDIA

PRODUCTION : ND-226, TANDA ROAD, JALANDHAR CITY-144 008 (PUNJAB), INDIA

PHONES : 094786-64645, 0181-5014275, 0181-3811125

CUSTOMER CARE : For any queries, please contact - 094786-14148

EMAIL : pv_books@yahoo.com

Online Shop : www.pvbooks.in

Also Buy at www.amazon.in 

© Copyrights Reserved

All rights reserved. No part of this publication may be reproduced or used in any form or by any means-photographic, electronic or mechanical including photocopying, recording, taping or information storage and retrieval systems-without the written permission of the publishers

ISBN 97815-43345-19-3

TradeMark No. 1350444

Edition 2021

PRICE : ₹ 525/-

Illustrators : Aakriti Jain

Printed and bound in India


by Choice Books and Printers Pvt. Ltd.

Exclusively marketed and distributed by PV books

For sale only in India, Nepal, Bangladesh, Sri Lanka and U.A.E.

The publishers make no representation, implied with regard to the accuracy of the contained in this book and cannot accept responsibility for any errors or omissions.




(Dr. R. O. Ganjivale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgoa (Moghe), Wardha

UNIT I Concepts of Quality Control Assurance 1-90

- ✓ 1.1 Concept, Evolution and Scope of Quality Control and Quality Assurance
✓ 1.1.2 GLP (Good Laboratory Practices) ✓ 1.3 GMP (Good manufacturing Practices) 35, 1.4 ICH Guidelines 57, 1.5 CPCSEA Guidelines 76


UNIT II cGMP Guidelines 91-143

- 2.1. Definition 91, 2.2. General Requirements 93, 2.3. Warehousing Area 94, 2.4. Production area 95, 2.5. Ancillary Areas 96, 2.6. Quality Control Area 96, 2.7. Personnel 97, 2.8. Health, clothing and sanitation of workers 97, 2.9. Manufacturing Operations and Controls 98, 2.10. Sanitation in the Manufacturing Premises 99, 2.11. Raw Materials 100, 2.12. Equipment 100, 2.13. Documentation and Records 101, 2.14. Labels and other Printed Materials 102, 2.15. Quality Assurance 102, 2.16. Self-Inspection and Quality audit 103, 2.17. Quality Control System 104, 2.18. Specification 105, 2.19. Master Formula Records 106, 2.20. Packing Records 107, 2.21. Batch Packaging Records 107, 2.22. Batch Processing Records 107, 2.23. Standard Operating Procedures (SOPs) and Records 108, 2.24. Reference samples 110, 2.25. Reprocessing and Recoveries 110, 2.26. Distribution records 111, 2.27. Validation and Process Validation 111, 2.28. Product recalls 111, 2.29. Complaints and Adverse Reactions 112, 2.30 Site Master File 112, 2.31. General 114, 2.32. Buildings and Civil Works 115, 2.33. Air Handling System (Central Air-Conditioning) 116, 2.34. Environmental Monitoring 117, 2.35. Garments 117, 2.36. Sanitation 118, 2.37. Equipment 119, 2.38. Water and Steam Systems 119, 2.39. Manufacturing Process 120, 2.40. Form-Fill-Seal Technology or Blow, Fill-Seal Technology 121, 2.41. Product Containers and closures 123, 2.42. Documentation 124, 2.43. Plant Layout 125, 2.44. Good warehousing practices (GWP) 126

UNIT III Analysis & In-Process Quality Control 144-167

- 3.0 Analysis of raw materials and finished products 144, 3.1 Analysis of packaging materials 146, 3.2 Package Testing Procedures 146, 3.3 In-process quality control (IPQC) and finished product (FPQC) 156




(Dr. R. O. Ganjivale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgunr (Moghe), Wardha

4.0 Document **168**, 4.1 Documentation **168**, 4.2 Retention of documents **173**, 4.3 Retrieval of documents **174**, 4.4 SOP **174**, 4.5 Revision of SOP **180**, 4.6 Preparation, Approval and Authorization of SOP **180**, 4.7 Implementation of SOP **181**, 4.8 Issuance and retrieval procedure **181**, 4.9 Revision of SOP **181**, 4.10 Master batch record/ Master Formula Record **185**, 4.11 Batch Manufacturing Record **190**, 4.12 Quality Audit Plan and Report **199**, 4.13 Elements of systemic audit program **204**, 4.14 GMP regulation format **205**, 4.15 Audit reports **207**, 4.16 Specification and test procedure **208**, 4.17 Reports **210**, 4.18 Distribution Records **210**, 4.19 Electronic Data Handling **213**, 4.20 Concepts of controlled and uncontrolled documents **214**, 4.21 Drug Master File **215**, 4.22 Submissions to Drug Master Files **219**, 4.23 Common Technical Document (CTD) and Electronic Common Document (eCTD) **221**, 4.24 Concept of regulated and non-regulated markets **226**

5.1 Manufacturing Operations and Control **230**, 5.2 Sanitation of manufacturing premises **231**, 5.3 Mix-Ups and Cross Contamination **232**, 5.4 Processing of intermediate and bulk products **234**, 5.5 Packaging Operations **235**, 5.6 I.P.Q.C. in manufacturing and packaging **237**, 5.7 Release of finished products **238**, 5.8 Process deviations **239**, 5.9 Charge in of components **239**, 5.10 Time limitations on production **240**, 5.11 Drug product inspection **241**, 5.12 Expiration dating **241**, 5.13 Calculation of yield **242**, 5.14 Production record review **243**, 5.15 Change Control **244**, 5.16 Changes in pharmaceutical operations **245**, 5.17 SOP for change control program **247**, 5.18 Reprocessing **249**, 5.19 Drug product salvaging **249**, 5.20 Handling of Waste and Scrap Disposal **249**, 5.21 Regulatory Bodies that oversee Pharmaceutical Waste Management **250**, 5.22 Type of Waste **250**, 5.23 Characteristic of Hazardous wastes **251**, 5.24 Objective of pharmaceutical waste treatment **252**, 5.25 Waste product Disposal Procedure **253**, 5.26 Schedule M of drug and cosmetics act, gives guidelines in this regard **254**, 5.27 WHO guidelines **255**, 5.28 Records **255**, 5.29 Intellectual Property Rights **255**, 5.30 Registered Marks **257**, 5.31 Patents **257**, 5.32 Copyright **257**

Bibliography


Index



(Dr. R. O. Ganjivale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Dorgnau (Steghe), Wardha

As per new
PCI
syllabus

PHARMACEUTICAL BIOTECHNOLOGY



Mrinal Sharma
Pradeep Goyal
Ashish Budhrani
Sourabh Kosey



R. O. Ganjiwale
(Dr. R. O. Ganjiwale)

Principal

PRINCIPAL

Institute of Pharmaceutical Education & Research
Borgun (Mighe), Wardha

Our other useful titles

Human Anatomy and Physiology II
Pathophysiology
Computer Applications in Pharmacy
Environment Sciences
Lab Manual of Microbiology
Lab Manual of Pharmaceutical Engineering
Lab Manual of Pharmaceutical Analysis
Pharmaceutical Validation
Lab Manual of Pharmacology
Lab Manual of Pharmacognosy and Phytochemistry I
Lab Manual of Organic chemistry I
Pharmacognosy and Phytochemistry I
Medicinal Chemistry II
Medicinal Chemistry I

For details visit, sites.google.com/site/detailsofbooks

The matter and format is copyrighted under copyright act by Author and Publisher. All rights of matter and its format are reserved by Publisher and Author. No part of the book can be reproduced, stored in or introduced into a retrieval system in any form or by any means (electronic, mechanical, photocopying, recording or any other) without the prior written permission of Publisher. The violation of copyright and any kind of plagiarism would be liable for legal action against the person. All disputes will be settled in Ghaziabad Court. Publisher is not at all responsible for any kind of plagiarism.

ISBN 978-93-84875-73-2


Cost Rs. 292 only

Premiere Edition 2021

© Publisher and Authors

Acknowledement and Disclaimer: *The author and publisher of this book has tried their best to ensure However, the author and pu implied, with regard to the liable in any event for any da statements.*




(Dr. R. O. Ganjwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgun (Aitgh), Wardha

ct.
or
be
ise


**Published by Dr. Chanchal Mittal for UNNATI PUBLICATIONS, 9,
SONA ENCLAVE, Modinagar, Ph: 09917436436, 09837007439.
e-mail at unnati_publications@gmail.com.**



A Text Book of
Human
Anatomy &
Physiology



*Strictly As Per Syllabus Framed under Education Regulation 2020 Prescribed for
D. Pharmacy, First Year by Pharmacy Council of India*



(Dr. R. O. Ganjiwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgun (Moghe), Wardha

Ashish Budhrani
Dr. Md. Rageeb Md. Usman
Pradeep Golani
Dr. Mohammed Zuber Shaikh

An Imprint of

S.VIKAS AND COMPANY (MEDICAL PUBLISHERS)

ADMIN : ND-106, BIKRAMPURA, JALANDHAR CITY-144 008 (PUNJAB), INDIA

SALES : ND-227, TANDA ROAD, JALANDHAR CITY-144 008 (PUNJAB), INDIA

PRODUCTION : ND-226, TANDA ROAD, JALANDHAR CITY-144 008 (PUNJAB), INDIA

PHONES : 094786-64645, 0181-5014275, 0181-3811125

CUSTOMER CARE : For any queries, please contact - 094786-14148

EMAIL : pv_books@yahoo.com

Online Shop : www.pvbooks.in

Also Buy at www.amazon.in



© Copyrights Reserved

All rights reserved. No part of this publication may be reproduced or used in any form or by any means-photographic, electronic or mechanical including photocopying, recording, taping or information storage and retrieval systems-without the written permission of the publishers

ISBN 97815-43345-43-8

TradeMark No. 1350444

Edition 2022

PRICE : ₹ 175-

Illustrators : Aakriti Jain

Printed and bound in India


by Choice Books and Printers Pvt. Ltd.

Exclusively marketed and distributed by PV books

For sale only in India, Nepal, Bangladesh, Sri Lanka and U.A.E.

The publishers make no representation, expressed or implied with regard to the accuracy of the information contained in this book and cannot accept legal responsibility for any errors or omissions.





(Dr. R. O. Ganjivale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgnour (Meghe), Wardha

CONTENTS

S.No.	TOPIC	Page No.
Chapter 1	Scope of anatomy and physiology	1-4
Chapter 2	Structure of cell: components and its functions	5-9
Chapter 3	Tissues of the human body	10-14
Chapter 4	Osseous system	15-35
Chapter 5	Haemopoietic system	36-43
Chapter 6	Lymphatic system	44-47
Chapter 7	Cardiovascular system	48-56
Chapter 8	The Respiratory system	57-60
Chapter 9	The digestive system	61-69
Chapter 10	Skeletal muscles	70-75
Chapter 11	Nervous system	76-81
Chapter 12	The Sensory organs	82-89
Chapter 13	Urinary system	90-95
Chapter 14	The Endocrine system	96-102
Chapter 15	The Reproductive system	103-110
	Index	(i)-(ii)




(Dr. R. O. Ganjivale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgnon (Meghe), Wardha

A Text Book of
**PHARMACEUTICAL
CHEMISTRY-I**

*Strictly As Per Syllabus Framed under Education Regulation 2020
Prescribed for D. Pharmacy, First Year by Pharmacy Council of India*

**Pradeep Golani
Ashish Budhrani
Dr. Megha Verma
Dr. Md. Rageeb Md. Usman**



Dr. R. O. Ganjwale
(Dr. R. O. Ganjwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borguon (Meghe), Wardha

Pee Vee (Regd.)

An Imprint of

S. VIKAS AND COMPANY (MEDICAL PUBLISHERS)

ADMIN : ND-106, BIKRAMPURA, JALANDHAR CITY-144 008 (PUNJAB), INDIA

SALES : ND-227, TANDA ROAD, JALANDHAR CITY-144 008 (PUNJAB), INDIA

PRODUCTION : ND-226, TANDA ROAD, JALANDHAR CITY-144 008 (PUNJAB), INDIA

PHONES : 094786-64645, 0181-5014275, 0181-3811125

CUSTOMER CARE : For any queries, please contact - 094786-14148

EMAIL : pv_books@yahoo.com

Online Shop : www.pvbooks.in

Also Buy at www.amazon.in



© Copyrights Reserved

All rights reserved. No part of this publication may be reproduced or used in any form or by any means—photographic, electronic or mechanical including photocopying, recording, taping or information storage and retrieval systems—without the written permission of the publishers

ISBN 97815-43345-50-6

TradeMark No. 1350444

Edition 2022

PRICE : ₹ 295/-

Illustrators : Aakriti Jain

Printed and bound in India


by Choice Books and Printers Pvt. Ltd.

Exclusively marketed and distributed by PV books

For sale only in India, Nepal, Bangladesh, Sri Lanka and U.A.E.

The publishers make no representation implied with regard to the accuracy contained in this book and cannot be held responsible for any errors or omissions.




(Dr. R. O. Ganjiwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgnour (Moghe), Wardha

CONTENTS


Chapter 1	Introduction to Pharmaceutical Chemistry	1-23
	1.1. Introduction to Pharmaceutical chemistry- Scope and Objectives 1, 1.2. Sources and types of errors 2, 1.3 Impurities & their Sources 9	
Chapter 2	Volumetric Analysis	24-39
	2.1 Fundamentals of volumetric analysis 24, 2.2. Neutralisation Titrations (acid - base titration) 26, 2.3 Non aqueous titration 28, 2.4 Precipitation Titrations 31, 2.5 Complexometric Titrations 33, 2.6 Oxidation-Reduction Titration 34, 2.7 Instrumental Analysis 35, 2.8 Gravimetric Analysis 35	
Chapter 3	Inorganic Pharmaceuticals	40-65
	3.1 Haematinics 40, 3.2 Antacids 45, 3.3 Antimicrobial agents 50, 3.4 Dental products 56, 3.5 Medicinal Gases 61	
Chapter 4	Introduction to Nomenclature	66-82
	4.1 Introduction 66, 4.2 Simple organic groups 66, 4.3 Heterocyclic compounds 72, 4.4 Stereochemical notations 79	
Chapter 5	Drugs Acting on Central Nervous System	83-111
	5.1 General anaesthetics 83, 5.2 Sedative and hypnotics 86, 5.3 Antipsychotics 90, 5.4 Anticonvulsants or antiepileptics 95, 5.5 Antidepressant drugs 103	
Chapter 6	Autonomic Nervous System (A.N.S.)	112-141
	6.1 Introduction to ANS 112, 6.2 Sympathomimetic agents/adrenergic drugs 113, 6.3 Direct acting agents (adrenergic agonists) 113, 6.4 Indirect acting agents 120, 6.5 Agents with mixed mechanism 121, 6.6 Adrenergic antagonist 124, 6.7 Alpha-adrenergic blocking agent 124, 6.8 Beta-adrenergic blocking agents 126, 6.9 Cholinergic drugs 129, 6.10 Acetylcholine analogues 129, 6.11 Cholinestrase inhibitors 131, 6.12 Cholinergic blocking agents 134, 6.13 Amino-alcohol esters 135, 6.14 Synthetic cholinergic blocking agents 138	
Chapter 7	Cardiovascular Drugs	142-154
	7.0 Introduction 142, 7.1 Antiarrhythmic drugs 142, 7.2 Antihypertensive drugs 148, 7.3 Anti-anginal drugs 153	
Chapter 8	Diuretics	155-162
	8.1 Introduction 155, 8.2 Classification 155, 8.3 Thiazides 156, 8.4 Carbonic anhydrase inhibitor 157, 8.5 High ceiling diuretics 158, 8.6 Osmotic diuretics 159, 8.7 Aldosterone antagonist 160	



Signature
(Dr. R. O. Ganjwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgas (Steph), Wardha

Chapter 9	Hypoglycemic Agents	163-171
	9.1 Introduction 163, 9.2 Classification 163, 9.3 Insulin 164, 9.4 Sulphonylureas 165, 9.5 Biguanides 166, 9.6 Thiazolidinediones 167, 9.7 Meglinitides 168, 9.8 Gliflozins 169, 9.9 Gliptins 170	
Chapter 10	Analgesic and Anti-Inflammatory Agents	172-188
	10.1 Introduction 172, 10.2 Analgesia 172, 10.3 Narcotic analgesics 173, 10.4 Narcotic antagonist 178, 10.5 Anti-inflammatory agents 178, 10.6 Non-steroidal anti-inflammatory drugs (NSAIDs) 178	
Chapter 11	Anti-Infective Agents	189-220
	11.0 Introduction 189, 11.1 Antifungal agents 190, 11.2 Urinary tract anti-infective agents 195, 11.3 Antitubercular drugs 198, 11.4 Antiviral agents 204, 11.5 Antimalarial drugs 209, 11.6 Sulphonamide 214	
Chapter 12	Antibiotics	221-230
	12.1 Introduction 221, 12.2 Definitions 221, 12.3 Classification 221, 12.4 B-Lactam antibiotics 222, 12.5 Aminoglycoside antibiotics 224, 12.6 Tetracycline antibiotics 224, 12.7 Macrolide antibiotics 226, 12.8 Lincosamide antibiotics 227, 12.9 Miscellaneous antibiotics 228	
Chapter 13	Anti-Neoplastic Drugs	231-241
	13.1 Introduction 231, 13.2 Definition 231,, 13.3 Classification 231, 13.4 Cyclophosphamide 232, 13.5 Busulfan 232, 13.6 Cisplatin 233, 13.7 Dactinomycin 234, 13.8 Doxorubicin 234, 13.9 Fluorouracil 235, 13.10 Mercaptopurine 236, 13.11 Methotrexate 237, 13.12 Vinblastine 238, 13.13 Dromostanolone 238	
	Bibliography	242
	Index	(i)-(iv)




 (Dr. R. O. Ganjiwale)
 Principal
PRINCIPAL
 Institute of Pharmaceutical Education & Research
 Borgou (Moghe), Wardha

PHOTOPHYSICS AND NANOPHYSICS IN THERAPEUTICS

Edited by
Nilesh M. Mahajan
Avneet Saini
Nishikant A. Raut
Sanjay J. Dhoble



R. O. Ganjiwale
(Dr. R. O. Ganjiwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgun (Moghe), Wardha

Part I Phototherapeutics

1. Phototherapy: A critical review

Nilesh Rarokar, Shailendra Gurav, Dadasaheb M. Kokare, Vijay Kale, Nishikant A. Raut

1.1 Introduction	3
1.2 Background	4
1.2.1 Historical perspective of phototherapy	4
1.2.2 Overview on various types of phototherapies	5
1.3 Various light sources and methods of phototherapy	7
1.3.1 Fluorescent tubes	7
1.3.2 Halogen spotlights	7
1.3.3 Fiberoptic blankets	7
1.3.4 Light-emitting diodes	7
1.3.5 Filtered sunlight	7
1.4 Applications and limitations of phototherapy	8
1.4.1 Application in neonatal jaundice	8
1.4.2 Application for morphea, scleroderma, and other sclerosing skin conditions	8
1.4.3 Application for cancer	8
1.4.4 Limitations of home phototherapy and sunlight	9
1.5 Recent developments and future scopes	9
1.5.1 The immunoregulatory effects of phototherapy: Possible pathways	9
1.5.2 Handheld phototherapy: Targeting difficult-to-treat psoriasis in the office and at home	10
1.5.3 The excimer laser: A potential new indication and a novel dosimetry protocol	10
1.5.4 Phototherapy and biologic agents: Combination therapy for recalcitrant psoriasis	11
1.5.5 Future scope	11
References	11

Renuka K. Mahajan, Dadasaheb M. Kokare, Nishikant A. Raut, Prakash R. Itankar

2.1 Introduction	15
2.1.1 The epidermis	15
2.1.2 The hypodermis	17
2.2 Major functions of the skin	17
2.3 Skin diseases and their etiology	18
2.4 Bacterial skin diseases	19
2.5 Fungal skin diseases	20
2.6 Viral skin diseases	20
2.7 Tropical ulcers	20
2.8 HIV related skin diseases	20
2.9 Pigmentation disorders	21
2.10 Parasitic infections	21
2.11 Tumors and cancers	21
2.12 Trauma	21
2.13 Skin tests	21
2.14 Heliotherapy	21
2.15 Naturopathy modalities on inflammation and immunity	22
2.16 Phototherapy for skin diseases	22
2.17 Methods	23
2.17.1 UVB radiations	23
2.17.2 UVA radiation	23
2.17.3 PUVA	23
2.17.4 Diseases and their treatment using phototherapy	24
2.17.5 Limitations of phototherapy for skin diseases	25
2.17.6 Side effects of phototherapy	26
2.17.7 Recent development and future scope	26
2.18 Concluding remark	26
References	27

3. Phototherapy: The novel emerging treatment for cancer

Sagar Trivedi, Nishant Awandekar, Milind Umekar, Veena Belgamwar, Nishikant A. Raut

3.1 Introduction	31
------------------	----



(Dr. R. O. Ganjiwale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgoo (Meghe), Wardha

3.2	Photophysics and photochemistry	32	4.2	Basic concept of photodynamic therapy	52
3.2.1	Type I mechanism of photodynamic reaction	32	4.2.1	Photosensitizers	52
3.2.2	Type II mechanism of photodynamic reaction	33	4.3	Working mechanism	62
3.3	Photodynamic targets at the molecular level	33	4.3.1	Mechanism of cell death following photodynamic therapy	64
3.3.1	Proteins	33	4.4	Advantages and disadvantages of photodynamic therapy	65
3.3.2	Photodynamic therapy-induced lipid peroxidation	34	4.4.1	Apoptosis in photodynamic therapy	65
3.3.3	Photosensitized modification of nucleic acids	34	4.4.2	Immunological effects of photodynamic therapy	67
3.4	Light source	35	4.4.3	Biological effects of photodynamic therapy	69
3.4.1	Near infrared (NIR) light	35	4.4.4	Summarizing the advantages and disadvantages of photodynamic therapy	71
3.4.2	X-ray	36	4.5	Essential wavelength region in photodynamic therapy	72
3.4.3	Incoherent light	37	4.6	Recent developments in photodynamic therapy	74
3.4.4	Internal light	37	4.6.1	Metal-organic frameworks	74
3.5	Changes in cell signaling after photodynamic therapy	37	4.6.2	Photoactive materials for wavelength response	75
3.5.1	Calcium	37	4.6.3	Photodynamic therapy and hypoxia-controlled nanomedicine	76
3.5.2	Lipid metabolism	38	4.7	Future scopes and perspectives	77
3.5.3	Tyrosine kinases	38	References	79	
3.5.4	Transcription factors	39			
3.5.5	Cellular adhesion	39			
3.5.6	Cytokines	39			
3.5.7	Stress response	39			
3.5.8	Hypoxia and angiogenesis	39			
3.6	Method of excitation for photosensitizing agents	40	5. Photodynamic therapy for cancer treatment		
3.6.1	Intermolecular chemically induced electronic excitation	40	Sagar Trivedi, Anita Paunikar, Nishkant Raut, Veena Bolganwar		
3.6.2	Resonance energy transfer excitation	40	5.1	Introduction	89
3.6.3	Two-stage photosensitizer excitation/excitation by radiation energy transfer intermediary	41	5.2	Background of photodynamic therapy	90
3.6.4	Cherenkov radiation energy transfer	41	5.2.1	Origin of photodynamic therapy	90
3.7	Photodynamic therapy modifications	42	5.2.2	Mechanism of photodynamic therapy	90
3.7.1	Nanotechnology on photodynamic therapy	42	5.2.3	Working principle of photodynamic therapy	90
3.7.2	Application of liposomes and lipoproteins	42	5.2.4	Mechanism of photodynamic therapy in treatment of cancer	92
3.7.3	Photodynamic therapy supported by electroporation	43	5.3	Novel strategies in photodynamic therapy	93
3.8	Conclusion	43	5.3.1	Metronomic photodynamic therapy	93
Acknowledgment		43	5.3.2	Photodynamic therapy molecular beacons	93
Statement of Informed consent		43	5.3.3	Nanotechnology in photodynamic therapy	93
Conflict of interest		43	5.4	Role of photosensitizing agents in photodynamic therapy	94
References		43	5.5	Application of photodynamic therapy in treatment of various cancers	102
4. Fundamentals of photodynamic therapy			5.5.1	Skin tumors	103
Mrunal M. Yawalkar, Samvit Menon, Hendrik C. Swart, Sanjay J. Dhoble			5.5.2	Head and neck tumors	103
4.1	Introduction	51	5.5.3	Digestive system tumors	103



5.5.4 Urinary system tumors	103	7.2.3 Types of external beam radiation therapy	141
5.5.5 Brain tumors	104	7.2.4 General indications for the radiotherapy	143
5.5.6 Nonsmall cell lung cancer and mesothelioma	105	7.2.5 Intent of radiotherapy treatment	143
5.6 Recent developments, future scope, and challenges	105	7.2.6 Types of cancer treated using radiotherapy	144
5.7 Conclusion	106	7.2.7 The role of radiotherapy in cancer control	144
Acknowledgment	106	7.3 Development of radiation physics	145
References	106	7.3.1 History	145
6. Photodiagnostic techniques		7.3.2 External radiotherapy	146
<i>Anurag Luharia, Gaurav Mishra, Nilesh Haran, Sanjay J. Dhole</i>		7.3.3 Clinical radiation generators	147
6.1 Introduction	115	7.3.4 Dose planning	148
6.1.1 Ionizing radiations	115	7.4 Recent advancement in radiotherapy	149
6.2 Fundamentals of light used in diagnostic techniques	116	7.4.1 Instigation	149
6.2.1 X-ray production	118	7.4.2 Radiotherapy principle and mechanism	149
6.2.2 X-ray beam intensity	119	7.4.3 Technology development	150
6.2.3 Target material	120	7.4.4 Image-guided radiotherapy treatment	151
6.2.4 Voltage applied	120	7.4.5 Adaptive radiotherapy	152
6.2.5 X-ray tube current	120	7.4.6 Stereotactic radiosurgery and radiotherapy	152
6.3 Various photo diagnostic techniques	120	7.4.7 Particle therapy	152
6.3.1 Plain radiography and digital radiography	120	7.4.8 Summary	153
6.3.2 Computed tomography	121	7.5 Radiosurgery for noncancerous tumor and diseases	153
6.3.3 Fluoroscopy	123	7.5.1 Introduction	153
6.3.4 Digital subtraction angiography	123	7.5.2 History	153
6.3.5 Digital radiography and picture archival and communication system	124	7.5.3 Treatment	154
6.3.6 Dual energy X-ray absorptiometry	124	7.5.4 Systems overview	154
6.3.7 Dual energy computed tomography	124	7.6 Summary and conclusion	157
6.3.8 Orthopantomography	124	References	157
6.4 Physics of photodiagnostic techniques	125	8. Physics in treatment of cancer radiotherapy	
6.4.1 Interaction of radiation with matter	125	<i>Ravindra B. Shende, Sanjay J. Dhole</i>	
6.4.2 Importance of interaction in tissue	127	8.1 Introduction	163
6.4.3 Picture archiving and communication system	130	8.1.1 Physics of radiotherapy	163
6.5 Opportunities, challenges, and limitations of photodiagnostic techniques	134	8.1.2 Structure of matter	163
References	135	8.1.3 Atom	163
7. The role of physics in modern radiotherapy: Current advances and developments		8.1.4 Nucleus	164
<i>Anurag Luharia, Gaurav Mishra, D. Saroj, V. Sonwani, Sanjay J. Dhole</i>		8.1.5 Types of radiation	164
7.1 Introduction	139	8.1.6 X-rays	165
7.2 Role of radiotherapy in cancer treatment	140	8.1.7 Gamma rays	166
7.2.1 What is radiotherapy and how it works?	140	8.1.8 Particulate radiation	166
7.2.2 Types of radiotherapy	141	8.1.9 Interaction of radiation with matter	166
		8.1.10 Interaction of photon beam (X-rays or γ rays)	166
		8.1.11 Coherent scattering	169
		8.1.12 Photoelectric effect	169
		8.1.13 Compton effects	170
		8.1.14 Pair production	170
		8.1.15 Photodisintegration	171



8.1.16	Interaction of charged particle	171	8.5.4	Particle fluence	188
8.1.17	Electron and electron interaction	172	8.5.5	Energy fluence	188
8.1.18	Electron and nucleus interaction	172	8.5.6	Exposure	188
8.1.19	Interaction of heavy charged particle	172	8.5.7	Kerma	188
8.1.20	Biological effect of radiation	173	8.5.8	Absorbed dose	189
8.1.21	Linear energy transfer	174	8.5.9	Methods of radiation dosimetry and dosimeters in radiation therapy	189
8.1.22	Relative biological effectiveness	174	8.5.10	Ionization chamber dosimetry	189
8.2	Principle of radiotherapy	175	8.5.11	Film dosimetry	189
8.2.1	Radiotherapy facility	175	8.5.12	Luminescence dosimetry	190
8.3	Traditional facility in treatment of radiotherapy	175	8.5.13	Thermoluminescence	190
8.3.1	Superficial therapy	175	8.5.14	Optically stimulated luminescence	191
8.3.2	Orthovoltage therapy or deep therapy	175	8.5.15	Semiconductor dosimetry	191
8.3.3	Supervoltage therapy machines	176	8.5.16	Physical and clinical dosimetry in radiotherapy	191
8.3.4	Cobalt-60 teletherapy unit	176	8.5.17	Physical dosimetry	191
8.3.5	Betatron and microtron	176	8.5.18	Clinical dosimetry	192
8.3.6	Advance facility in treatment of radiotherapy	177	References	192	
8.3.7	Linear accelerator (Linac)	177	9. Role of carbon ion beam radiotherapy for cancer treatment		
8.3.8	Tomotherapy	178	<i>Vibha Chopra, Nirupama S. Dhole, Ballarshna Vengadeswaran, Sanjay J. Dhole</i>		
8.3.9	CyberKnife	178	9.1	Introduction	193
8.3.10	Proton and light ion therapy	178	9.2	Radiation therapy for the treatment of cancer	193
8.3.11	Cyclotron	178	9.2.1	Gamma ray therapy	194
8.3.12	Synchrotron and synchrocyclotron	179	9.2.2	Proton therapy	194
8.3.13	Add-on facility in treatment of radiotherapy	179	9.2.3	Ion beam therapy	194
8.3.14	Conventional simulator	179	9.3	Role of carbon ion beam therapy	195
8.3.15	CT simulator	180	9.4	Development of TLD materials for carbon ion beam therapy	195
8.3.16	Commissioning of radiotherapy facility and quality assurance	180	9.4.1	Lithium-based phosphors	195
8.3.17	Technique of radiotherapy	180	9.4.2	Calcium-based phosphors	198
8.3.18	External beam radiation therapy	181	9.4.3	Some other phosphors	200
8.3.19	Conventional treatment techniques in EBRT	181	9.5	Conclusion	202
8.3.20	Three-dimensional conformal radiation therapy	181	References	202	
8.3.21	Intensity modulated radiation therapy	182			
8.3.22	Rotational therapy or volumetric modulated arc therapy (VMAT)	184			
8.3.23	Stereotactic radiosurgery and stereotactic radiotherapy	184			
8.3.24	Image-guided radiotherapy	184			
8.3.25	Internal beam radiation therapy or brachytherapy	185			
8.3.26	Process and treatment of radiotherapy	186			
8.4	Patient preparation and simulation	187			
8.5	Target delineation and treatment planning	187			
8.5.1	Treatment verification and treatment delivery	187			
8.5.2	Dosimetry in radiation therapy	188			
8.5.3	Activity	188			



10.3	Properties of materials	210
10.3.1	Factors affecting properties of a material	210
10.4	Rationale of nanoparticle physics with diverse functions involving nanomaterials	211
10.5	Self-assembly of nanostructures	212
10.6	Clinical applications of nanomaterials physics	212
10.6.1	Applications of nanomaterials physics in cancer	212
10.7	Conclusion: Nanotechnology, physics, and clinical outcome	213
	Acknowledgments	214
	References	214

11. Nanotherapeutic systems for drug delivery to brain tumors

Keshav S. Moharir, Vinita Kale, Mallesh Kurakula

11.1	Introduction	217
11.2	An overview of brain tumors	218
11.2.1	Malignant brain tumors	218
11.2.2	Benign brain tumors	218
11.3	Barriers and challenges in the treatment of brain cancer	219
11.3.1	BBB as a main hurdle	219
11.3.2	Chemoresistance and efflux	220
11.3.3	Tumor microenvironment (TME) dynamics and lack of brain tumor classification based on genetics	220
11.3.4	Resistance due to cancer stem cells (CSCs) of gliomas and GBM	220
11.3.5	Lack of proper brain cancer mimicking models	221
11.4	Conventional vs nanomedicines in drug delivery for brain cancers	221
11.5	Approaches and mechanisms of nanocarriers for chemotherapeutic drug delivery to brain tumors	222
11.5.1	Passive targeting	222
11.5.2	Active targeting	222
11.5.3	Stimuli responsive nanocarriers systems	224
11.6	Types of nanotherapeutic platforms for drug delivery to treat brain cancer	225
11.6.1	Inorganic (metallic) nanoparticles	225
11.6.2	Lipid-based and polymeric nanoparticles	228
11.7	Novel therapies to treat brain cancers	229
11.7.1	Artificial intelligence (AI)-enabled nanocarriers for oncotherapy	229
11.7.2	Gene-based nanotherapy	231

11.7.3	CRISPR/Cas 9-associated brain tumor therapy	232
11.7.4	Nose to brain drug delivery	232
11.8	Clinical translation of nanotherapeutic systems for brain cancers: From bench to bedside	232
11.9	Conclusion and future prospects	232
	References	233

12. Progress in nanotechnology-based targeted cancer treatment

Shagufta Khan, Vatsali Kilor, Dillesh Singhavi, Rindan Patil

12.1	Introduction	239
12.2	Tumor microenvironment: Comparison with normal cells	239
12.2.1	Angiogenesis and endothelial permeability in cancer	240
12.2.2	Microenvironment pH	240
12.2.3	Microenvironment temperature	240
12.3	Nanotechnology-based diagnosis of cancer	240
12.4	Nanotechnology-based drug targeting strategies in cancer	241
12.4.1	Passive targeting	241
12.4.2	Active targeting	242
12.4.3	Physical targeting	245
12.5	Progress in nanotherapeutics for treating breast and lung cancer	245
12.5.1	Breast cancer	245
12.5.2	Lung cancer	246
12.6	Future of nanotechnology in cancer treatment	247
12.7	Conclusion	248
	References	248

13. Nanotherapeutics for colon cancer

Nilesh M. Mahajan, Alap Chaudhari, Sachin More, Purushottam Gangane

13.1	Introduction	251
13.1.1	Anatomy	251
13.1.2	Pathogenesis and molecular pathways for CRC	252
13.1.3	Risk factors	253
13.1.4	Stages of CRC	254
13.1.5	Signs and symptoms	254
13.2	Diagnosis	254
13.2.1	Endoscopy	255
13.2.2	Imaging	255
13.2.3	Laboratory	255
13.2.4	Pathology	255



(Dr. R. O. Ganjivale)
Principal

PRINCIPAL
Institute of Pharmaceutical Education & Research
Borguon (Moghe), Wardha

13.3	Current therapies	256	15.	Role of nanocarriers for the effective delivery of anti-HIV drugs	
13.3.1	Conventional treatment strategies	256		<i>Rohini Kharwade, Nilesh M. Mahajan</i>	
13.3.2	Targeted therapy	259	15.1	Introduction	291
13.3.3	Targeted therapies using nanocarriers	260	15.1.1	HIV life cycle and pathogenesis	291
13.4	Nanodrug delivery in cancer therapy	261	15.1.2	Pathophysiology	293
13.4.1	Polymers used in formulations of NPs	261	15.2	Conventional antiretroviral therapy	293
13.5	Polymeric nanoparticles (PNPs)	262	15.3	Types of nanocarriers for antiretroviral drugs delivery	295
13.5.1	Lipid-based nanoparticles	263	15.3.1	Pure drug nanoparticles	296
13.5.2	Superparamagnetic Iron oxide nanoparticles (SPIONs)	263	15.3.2	Polymeric nanoparticles	297
13.5.3	Gold nanoparticles (AuNPs)	263	15.3.3	Dendrimers	299
13.5.4	Enteric-coated nanoparticles	264	15.3.4	Polymeric micelles	301
13.6	Conclusion	264	15.3.5	Liposomes	302
References		265	15.3.6	Solid lipid nanoparticles	303
14.	Nanoparticles for the targeted drug delivery in lung cancer		15.4	Nanotechnological approaches for antiretroviral therapy	304
	<i>Veená Belgamwar, Vidyadevi Bhojar, Sagar Trivedi, Miral Patel</i>		15.4.1	Immunotherapy for antiretroviral	304
14.1	Introduction	269	15.4.2	Gene therapy	305
14.1.1	Stages of LC	269	15.4.3	Vaccines	305
14.1.2	Current treatment strategies on LC	270	15.5	Nanotechnology for improving latency reservoir	306
14.1.3	Novel strategies for LC treatment by pulmonary route of administration	272	15.6	Conclusion	307
14.1.4	Pulmonary physiology and drug absorption	273	References		307
14.1.5	Role of nanoparticulate technology in the diagnosis and treatment of LC	273	16.	Drug delivery systems for rheumatoid arthritis treatment	
14.1.6	Nanocarriers used for the diagnosis of lung diseases	274		<i>Mangesh Bhalekar, Sachin Dubey</i>	
14.2	Nanocarriers in LC treatment	275	16.1	Introduction	311
14.2.1	Solid-lipid nanocarriers	275	16.1.1	Stages of rheumatoid arthritis	311
14.2.2	Polymetric nanocarriers	276	16.1.2	Causes of RA	311
14.2.3	Nanoemulsions as potential carrier in LC	276	16.1.3	Symptoms of RA	312
14.2.4	Metal-based NPs	277	16.1.4	Pathology of rheumatoid arthritis	312
14.2.5	Dendrimers-based drug delivery	277	16.2	Management of rheumatoid arthritis	314
14.2.6	Target-mediated targeted therapy	279	16.3	Targeted delivery strategies to inflamed synovium	314
14.2.7	Quantum dots (QDs) as a drug delivery system	279	16.4	Passive targeting	315
14.2.8	Bio-NPs for LC	280	16.4.1	Enhanced permeability and retention (EPR) effect	315
14.2.9	Hydrogel-based drug delivery for pulmonary cancer	281	16.4.2	Hypoxia and acidosis	315
14.2.10	Inhalation-based nanomedicine for pulmonary cancer	281	16.4.3	Stimuli responsive drug delivery	316
14.3	Marketed formulation	282	16.4.4	Angiogenesis	316
14.4	Toxicity issues of inhaled NPs	283	16.5	Active targeting	316
14.5	Conclusion	284	16.6	Factors for the selection of delivery system	316
References		285	16.6.1	Carrier type	316
			16.6.2	Particle size	316
			16.6.3	Shape	317
			16.6.4	Surface modifications	317
			16.6.5	Prolonged circulation time	317
			16.6.6	Strategies for active targeting	317



(Dr. R. O. Ganjivale)
Principal

PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgoa (Moghe), Wardha

Progress in nanotechnology-based targeted cancer treatment

Shagufta Khan^a, Vaishali Kilor^b, Dilesh Singhavi^a, Kundan Patil^c

^aDepartment of Pharmaceutics, Institute of Pharmaceutical Education and Research,

Borgaon (Meghe) Wardha, Maharashtra, India

^bDepartment of Pharmaceutics, Gurunanak College of Pharmacy, Nagpur, Maharashtra, India

^cDepartment of Pharmaceutics, Government College of Pharmacy, Amrawati, Maharashtra, India

12.1 Introduction


Cancer is a principal cause of death across the globe. The World Health Organization estimates that 13 million people will die by 2030 due to cancer (World Health Organization, 2008).

Despite so much progress in the diagnosis and understanding of cancer, its cure still seems to be out of grip. There are still many types of cancer that are very difficult to treat. Therefore, for effective cancer therapy, it is necessary to understand the cancer pathophysiology, discover new anticancer drugs and develop novel delivery systems which can deliver drug precisely to the cancer cells. It is highly desirable to have innovative treatments that are effective against tumors that have become resistant to conventional therapies.

Until recently, chemotherapy was the only choice to treat most advanced cancers. But these drugs destroy healthy cells in addition to the cancerous ones, causing toxic side blood count. Older patients, having anemia or poor ki

With the surge in targeted therapies, there has been act with the specific genes and proteins in cancer cel between the cancer cell and a normal cell, thus target





(Dr. R. O. Ganjivale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgaon (Meghe), Wardha

low

nter-

nces

well-



Nanotechnological Applications In Virology



R. Ganjivale
(Dr. R. O. Ganjivale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgnour (Moghe), Wardha

Edited by
Mahendra Rai
Alka Yadav



Front Matter

Copyright

Contributors

Preface

Chapter 1. Nanotechnological applications in old ...

Chapter 2. Nanotechnology-based innovations to ...

Chapter 3. Unique advantages of nanomaterials i...

Chapter 4. Application of nanomaterials as nano-...

Chapter 5. Personal protective equipment to prot...

Chapter 6. Nanotherapy approach to target ZIKA ...

Chapter 7. Nanotechnology: New frontiers in anti...

Chapter 8. Nanoparticle-based immunoassays for...

Chapter 9. Potential role of nanotechnology in th...

Chapter 10. Nanoformulations: A novel approach ...

Chapter 11. SARS, MERS, nSARS-CoV-2 infection...

Chapter 12. Origin, evolution, and pathogenesis ...

Chapter 13. Recent advancements and nanotechn...

Chapter 14. Strategies on functionalization of org...

Chapter 15. Nanovaccines against viral infections:
Current trends and future prospects

Chapter 16. Development of novel vaccines using...

Index

ACADEMIC
PRESS

Nanotechnological Applications in Virology

Developments in Applied Microbiology and Biotechnology

2022, Pages 315-328



Chapter 15 - Nanovaccines against viral infections: Current trends and future prospects

Shaguftha Khan^a, Aarti Belgamwar^a, Pramod Yeole^b

Show more ▾

+ Add to Mendeley Share Cite

<https://doi.org/10.1016/B978-0-323-99596-2.00014-5>[Get rights and content >](#)

Abstract

In recent years, nanovaccines have gained enormous interest for protection against viral infection because of their capability to provide enhanced specificity, potency, prevent premature degradation, and prolonged action. Nanocarriers including virus-like particles, virosomes, and viral cell-coated particles are being extensively investigated for the delivery of antigens and adjuvants. Nanocarriers, owing to their size and surface characteristics, are capable of activating and being taken up by the antigen-presenting cells readily without the use of adjuvants. This chapter focuses on the advances in nanovaccine development for combating viral infection and challenges in achieving long-term immunity against several viral infections. It will also throw light on single-shot vaccine technology that is stable at room temperature.



Prev



Signature
(Dr. R. O. Ganjivale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Bargoa (High), Warananagar

87
Next chapter in book

Nanovaccines against viral infections: Current trends and future prospects

Shagufta Khan^a, Aarti Belgamwar^a, and Pramod Yeole^b

^aDepartment of Pharmaceutics, Institute of Pharmaceutical Education and Research, Wardha, Maharashtra, India ^bDr. Babasaheb Ambedkar Marathwada University, Aurangabad, Maharashtra, India

OUTLINE

1	Introduction	315	4.5	Inorganic nanoparticles	322
2	Immune response against microbes	316	4.6	Liposomes	323
3	Immune response to vaccines	318	4.7	Cell membrane-coated NPs	324
4	Nanocarriers for vaccine delivery	318	4.8	Gene-based vaccines	324
	4.1 Virus-like particles (VLPs)	319	5	Conclusion and future perspectives	326
	4.2 Virosomes	321		References	326
	4.3 Polymeric nanoparticles (PNPs)	321		Further reading	328
	4.4 Chitosan nanoparticles	322			

1 Introduction

Conventional vaccines are incapable of controlling the amount of vaccine release and recognize the target tissue; therefore, the vaccine is dispersed throughout the body. Nanotechnology-based vaccines can control the release and deliver the antigen to the desired points.

Nanovaccines have the potential to target the part of the body from where an infection has originated, while control of antigens against d

egrity



(Dr. R. O. Ganjiwale)
(Dr. R. O. Ganjiwale)


Principal

PRINCIPAL

Institute of Pharmaceutical Education & Research
Borgnour (Steghe), Wardha

Chief Editor
Dr. Prabhat Kumar Chaturvedi

Volume - 2



Published by
Bright Sky Publications,
Office No.3, 1st Floor, Pocket - H34, Sec - 3,
Rohini, New Delhi-110085, India
Phone: +91-9911215212, +91-9999744933
Email: brightskypublications@gmail.com



Attribution-NonCommercial-ShareAlike
4.0 International (CC BY-NC-SA 4.0)



Dr. R. O. Ganjivale
(Dr. R. O. Ganjivale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgun (Meghe), Wardha



Bright Sky Publications
New Delhi

Boron: A Micronutrient yet Indispensable

Akhil Nagar, Ruchita Bardiya, Atul Bendale, Kishor Danao and Nilesh Karande

Abstract


Boron is a metalloid that also serves as a micronutrient for humans (1-2 mg daily) and plants (1-2 μg) needed in trace amounts for healthy growth and development. In monocotyledonous and dicotyledonous plants, boron is essential for cell wall synthesis, membrane functionalization, cell division, root elongation, cell differentiation, plant hormonal, and generative growth. Boron is absorbed by plants in the form of Boric acid (96%) and borate anion (4%) via passive diffusion by the Boron transporter 1 while taking into account numerous parameters. Plants obtain boron mostly from the soil, followed by fertilizer and other water sources. Because boron is such a sensitive element, its deficiency and toxicity have a very narrow range. The main causes of deficiency are intensive cropping, liming of acid soils, inappropriate use of manure and chemical fertilizers, soil erosion, and frequent wet and dry conditions. Inadequate boron concentration affects the root, shoot, fruits, vegetables, and leaves of plants, as well as their growth, development, absorption, and reproductivity. Soil degradation is becoming a more serious problem for modern agriculture, as nearly 80% of the soil that was once useful for agriculture has been destroyed by our modern era, and soil micronutrient fertility status degradation is becoming a serious problem threatening modern agriculture's sustainability. We'll look at some of the most essential characteristics of boron in relation to plants, soil types, and boron shortage, as well as different sources of boron, its metabolism, and availability in plants, in this chapter. The numerous varieties of boron fertilizers available on the market, as well as their usage on distinct soil types.

Keywords: Boron, boron deficiency, sources, fertilizer, soil, Rhamnogalacturonan II (RG-II)

Introduction

Plants, like human beings, require boron for their development. There are




(Dr. R. O. Ganjivale)
Principal
PRINCIPAL
Institute of Pharmaceutical Education & Research
Borgun (Moghe), Wardha